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A B S T R A C T
Background
The treatment of people with acute abdominal pain differs if they have acute pancreatitis. It is important to know the diagnostic
accuracy of serum amylase, serum lipase, urinary trypsinogen-2, and urinary amylase for the diagnosis of acute pancreatitis, so that an
informed decision can be made as to whether the person with abdominal pain has acute pancreatitis. There is currently no Cochrane
review of the diagnostic test accuracy of serum amylase, serum lipase, urinary trypsinogen-2, and urinary amylase for the diagnosis of
acute pancreatitis.
Objectives
To compare the diagnostic accuracy of serum amylase, serum lipase, urinary trypsinogen-2, and urinary amylase, either alone or in
combination, in the diagnosis of acute pancreatitis in people with acute onset of a persistent, severe epigastric pain or diffuse abdominal
pain.
Search methods
We searchedMEDLINE, Embase, Science Citation Index Expanded, National Institute for Health Research (NIHRHTA and DARE),
and other databases until March 2017. We searched the references of the included studies to identify additional studies. We did
not restrict studies based on language or publication status, or whether data were collected prospectively or retrospectively. We also
performed a ’related search’ and ’citing reference’ search in MEDLINE and Embase.
Selection criteria
We included all studies that evaluated the diagnostic test accuracy of serum amylase, serum lipase, urinary trypsinogen-2, and urinary
amylase for the diagnosis of acute pancreatitis. We excluded case-control studies because these studies are prone to bias. We accepted
any of the following reference standards: biopsy, consensus conference definition, radiological features of acute pancreatitis, diagnosis
of acute pancreatitis during laparotomy or autopsy, and organ failure. At least two review authors independently searched and screened
the references located by the search to identify relevant studies.
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Data collection and analysis
Two review authors independently extracted data from the included studies. The thresholds used for the diagnosis of acute pancreatitis
varied in the trials, resulting in sparse data for each index test. Because of sparse data, we used -2 log likelihood values to determine
which model to use for meta-analysis. We calculated and reported the sensitivity, specificity, post-test probability of a positive and
negative index test along with 95% confidence interval (CI) for each cutoff, but have reported only the results of the recommended
cutoff of three times normal for serum amylase and serum lipase, and the manufacturer-recommended cutoff of 50 mg/mL for urinary
trypsinogen-2 in the abstract.
Main results
Ten studies including 5056 participants met the inclusion criteria for this review and assessed the diagnostic accuracy of the index
tests in people presenting to the emergency department with acute abdominal pain. The risk of bias was unclear or high for all of the
included studies. The study that contributed approximately two-thirds of the participants included in this review was excluded from
the results of the analysis presented below due to major concerns about the participants included in the study. We have presented only
the results where at least two studies were included in the analysis.
Serum amylase, serum lipase, and urinary trypsinogen-2 at the standard threshold levels of more than three times normal for serum
amylase and serum lipase, and a threshold of 50 ng/mL for urinary trypsinogen-2 appear to have similar sensitivities (0.72 (95% CI
0.59 to 0.82); 0.79 (95% CI 0.54 to 0.92); and 0.72 (95% CI 0.56 to 0.84), respectively) and specificities (0.93 (95% CI 0.66 to 0.99);
0.89 (95% CI 0.46 to 0.99); and 0.90 (95% CI 0.85 to 0.93), respectively). At the median prevalence of 22.6% of acute pancreatitis
in the studies, out of 100 people with positive test, serum amylase (more than three times normal), serum lipase (more than three times
normal), and urinary trypsinogen (more than 50 ng/mL), 74 (95% CI 33 to 94); 68 (95% CI 21 to 94); and 67 (95% CI 57 to 76)
people have acute pancreatitis, respectively; out of 100 people with negative test, serum amylase (more than three times normal), serum
lipase (more than three times normal), and urinary trypsinogen (more than 50 ng/mL), 8 (95% CI 5 to 12); 7 (95% CI 3 to 15); and 8
(95% CI 5 to 13) people have acute pancreatitis, respectively. We were not able to compare these tests formally because of sparse data.
Authors’ conclusions
As about a quarter of people with acute pancreatitis fail to be diagnosed as having acute pancreatitis with the evaluated tests, one should
have a low threshold to admit the patient and treat them for acute pancreatitis if the symptoms are suggestive of acute pancreatitis, even
if these tests are normal. About 1 in 10 patients without acute pancreatitis may be wrongly diagnosed as having acute pancreatitis with
these tests, therefore it is important to consider other conditions that require urgent surgical intervention, such as perforated viscus,
even if these tests are abnormal.
The diagnostic performance of these tests decreases even further with the progression of time, and one should have an even lower
threshold to perform additional investigations if the symptoms are suggestive of acute pancreatitis.
P L A I N L A N G U A G E S U M M A R Y
Blood and urine tests for the diagnosis of acute pancreatitis (sudden inflammation of pancreas)
Background
The pancreas is an organ in the abdomen (tummy) that secretes several digestive enzymes (substances that break down the food we eat)
into the pancreatic ductal system, which empties into the small bowel. The pancreas also contains the islets of Langerhans, which secrete
several hormones such as insulin (which helps regulate blood sugar). Acute pancreatitis is sudden inflammation of the pancreas, which
can lead to damage of the heart, lungs, and kidneys and cause them to fail. Acute pancreatitis usually manifests as upper abdominal
pain radiating to the back. However, there are several potential causes of upper abdominal pain. It is important to determine if someone
with abdominal pain has acute pancreatitis or another illness in order to start appropriate treatment. Blood tests such as serum amylase
and serum lipase, as well as urine tests such as urinary trypsinogen-2 and urinary amylase, can be used to determine if someone with
abdominal pain has acute pancreatitis. It is usually the case that a patient is considered to have acute pancreatitis only when amylase
or lipase levels are three times the upper limit of normal. With regard to urinary trypsinogen-2, a level of more than 50 ng/mL of
trypsinogen-2 in the urine is considered an indication of acute pancreatitis. With regard to urinary amylase, there is no clear-cut level
beyond which someone with abdominal pain is considered to have acute pancreatitis. At present it is unclear whether these tests are
equally effective or if one of the tests is better than the other in the diagnosis of acute pancreatitis in people with sudden-onset abdominal
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pain. We determined to resolve this question by performing a literature search for studies reporting the accuracy of the above mentioned
blood and urine tests. We included studies reported until 20 March 2017.
Study characteristics
We identified 10 studies reporting information on 5056 people with abdominal pain that started suddenly. The studies included
pancreatitis due to all causes.
Quality of evidence
All of the studies were of unclear or low methodological quality, which may result in arriving at false conclusions. We excluded the
study that contributed approximately two-thirds of the participants included in this review from the results of the analysis presented
below due to concerns about whether the participants included in the study are typical of those seen in the emergency department.
Key results
The accuracy of serum amylase, serum lipase, and urinary trypsinogen-2 in making the diagnosis of acute pancreatitis was similar.
About a quarter of people with acute pancreatitis fail to be diagnosed as having acute pancreatitis with these tests. The patient should
be admitted and treated as having acute pancreatitis, even if these tests are normal, if there is a suspicion of acute pancreatitis. As about
1 in 10 patients without acute pancreatitis may be wrongly diagnosed as having acute pancreatitis with these tests, it is important
to consider other conditions that require urgent surgery, even if these tests are abnormal. The diagnostic performance of these tests
decreases even further with the progression of time, and additional investigations should be performed if there is a suspicion of acute
pancreatitis.
B A C K G R O U N D
The pancreas is an abdominal organ that secretes several digestive
enzymes into the pancreatic ductal system, which empties into
the small bowel. It also houses the islets of Langerhans, which
secrete several hormones including insulin (NCBI 2014). Acute
pancreatitis is a sudden inflammatory process in the pancreas, with
variable involvement of adjacent organs or other organ systems
(Bradley 1993). The annual incidence of acute pancreatitis ranges
from 5 to 30 per 100,000 population (Roberts 2013; Yadav 2006).
In the last one to two decades there has been an increase in the
incidence of acute pancreatitis in the UK and USA (Roberts 2013;
Yang 2008). Acute pancreatitis is the most common gastrointesti-
nal (digestive tract) cause of hospital admission in the USA (Peery
2012). Gallstones and alcohol are the two main causes of acute
pancreatitis. Approximately 50% to 70% of cases of acute pancre-
atitis are caused by gallstones (Roberts 2013; Yadav 2006). Increas-
ing age, male gender, and lower socioeconomic class are associated
with a higher incidence of acute pancreatitis (Roberts 2013).
According to a consensus conference on the classification of acute
pancreatitis, the diagnosis of acute pancreatitis is generally made
when at least two of the following three features are present (Banks
2013).
• Acute onset of a persistent, severe epigastric pain often
radiating to the back.
• Serum lipase activity (or amylase activity) at least three
times greater than the upper limit of normal.
• Characteristic findings of acute pancreatitis on contrast-
enhanced computed tomography (CECT) and, less commonly,
magnetic resonance imaging (MRI) or transabdominal
ultrasonography.
Acute pancreatitis can be classified into interstitial oedematous
pancreatitis (diffuse or occasionally localised enlargement of the
pancreas due to inflammatory oedema as seen onCECT) or necro-
tising pancreatitis (necrosis involving either the pancreas or peri-
pancreatic tissues, or both) (Banks 2013). Approximately 90% to
95% of people with acute pancreatitis have interstitial oedema-
tous pancreatitis, while the remainder have necrotising pancreati-
tis (Banks 2013). Necrotising pancreatitis may be sterile or in-
fected (Banks 2013). Various theories exist as to how pancreatic
and peripancreatic tissues become infected, including spreading
of the infection from blood circulation, lymphatics, bile, from the
small bowel (duodenum) through the pancreatic duct, and migra-
tion through the large bowel wall (translocation) (Schmid 1999).
Local complications of acute pancreatitis include acute peripan-
creatic fluid collection, pancreatic pseudocyst, acute necrotic col-
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lection, and walled-off necrosis (Banks 2013). The systemic com-
plications of acute pancreatitis include worsening of pre-existing
illnesses, such as heart or chronic lung disease (Banks 2013). The
mortality rate following an attack of acute pancreatitis is between
6% and 20% (Roberts 2013; Yadav 2006). The mortality rate
depends upon the severity of acute pancreatitis and the presence
of infection. Acute pancreatitis can be classified as mild, moder-
ate, or severe, depending upon the presence of local or systemic
complications, transient organ failure involving one of more of
lungs, kidneys, and cardiovascular system (heart and blood vessels)
lasting up to 48 hours, or persistent failure of the same organs
mentioned above lasting beyond 48 hours. In mild pancreatitis,
there are no local complications, systemic complications, or organ
failure. In moderately severe acute pancreatitis, there may be lo-
cal or systemic complications or transient organ failure. In severe
acute pancreatitis, there is persistent organ failure (Banks 2013).
(See summary in Table 1.) Acute severe pancreatitis carries the
worst prognosis in terms of mortality, while mild pancreatitis has
the best prognosis (Banks 2013). Infected necrotising pancreatitis
carries a significantly worse prognosis than sterile necrotising pan-
creatitis, with an average in-hospital mortality of more than 30%
for people with infected necrotising pancreatitis, which increases
to more than 40% in the subgroup of people with organ failure in
addition to infection (Petrov 2010).
See Appendix 1 for a glossary of terms.
Target condition being diagnosed
Acute pancreatitis in people with acute epigastric pain or diffuse
abdominal pain.
Index test(s)
All of the index tests evaluated in this review are performed by the
laboratory technician and interpreted by the clinician.
Serum amylase
Amylase is an enzyme secreted by the pancreas. Various other tis-
sues including salivary glands, small intestine, ovaries, adipose tis-
sue, and skeletal muscles secrete amylase. There are two major
isoforms of amylase: pancreatic amylase and salivary amylase. The
normal range of amylase varies between laboratories, but is usu-
ally between 100 international units (IU)/L to 300 IU/L (Vissers
1999). Acute pancreatitis is one cause of increased amylase (hyper-
amylasaemia). The reason for this elevation is unclear, although
capillary leakage due to obstruction of venous and lymphatic
drainage of pancreatic and peripancreatic tissues, and transperi-
toneal absorption of amylase may be responsible (Vissers 1999).
In acute pancreatitis, serum amylase levels usually rise within 6
to 24 hours, peak at 48 hours, and decrease to normal or near
normal levels over the next 5 to 7 days (Vissers 1999). A common
threshold used is three times the normal limit (Banks 2013).
Serum lipase
Lipase is another enzyme secreted by the pancreas. Acute pancre-
atitis is the main reason for an increase in lipase, although a num-
ber of other conditions such as chronic pancreatitis, acute chole-
cystitis, and bowel obstruction can increase lipase activity (Vissers
1999). In acute pancreatitis, serum lipase levels usually rise within
4 to 8 hours, peak at 24 hours, and decrease to normal or near
normal levels over the next 8 to 14 days. Serum lipase remains
elevated for a longer period of time compared to the period of
elevation of serum amylase after acute pancreatitis (Vissers 1999).
A common threshold used is three times the normal limit (Banks
2013).
Urinary trypsinogen level
Autodigestion because of trypsinogen activation is one of the
mechanisms believed to result in acute pancreatitis. Since trypsino-
gen levels are elevated in acute pancreatitis, measurement of
urinary trypsinogen-2 (an isoenzyme of trypsinogen) has been
proposed as a test for diagnosing pancreatitis (Hedstrom 1994;
Hedstrom 1996; Hedstrom 1996c). In acute pancreatitis, urinary
trypsinogen levels usually rise to high levels within a few hours
and decrease in three days (Matull 2006). A common threshold
used is 50 ng/mL (Chang 2012).
Urinary amylase
Urinary amylase above 2000 IU/L is considered abnormal. Mea-
surement of urinary amylase has been proposed as a test for the
diagnosis of pancreatitis (Hedstrom 1996c; Kemppainen 1997c).
Clinical pathway
For people with acute onset of a persistent, severe epigastric pain
or with diffuse abdominal pain starting in the epigastric region
(or if the person is unsure about the region in which diffuse ab-
dominal pain began), clinical examination including recording of
blood pressure, pulse rate, and oxygen saturations (when available)
are performed. Routine blood tests such as full blood count, urea,
creatinine, and electrolytes are also performed. Blood tests such as
amylase and lipase (index tests being evaluated in this review) are
performed to confirm (or rule out) the diagnosis of acute pancre-
atitis. Radiological findings of acute pancreatitis evolve over a few
days and the radiological features may not be apparent in the early
stages, or may even be normal (Banks 2013; Vissers 1999), thus
one cannot rely on radiological tests to diagnose acute pancreatitis,
at least in the early stages. Radiological examination with CT scan
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or MRI is not routinely performed if a diagnosis of acute pan-
creatitis is suspected. If acute pancreatitis can be ruled out, other
causes of acute epigastric pain should be considered. Peptic ulcer,
functional dyspepsia, and gallstones can present with acute epigas-
tric pain (Gurusamy 2014; Moayyedi 2006). All of these alterna-
tive causes of epigastric pain are generally investigated and treated
after discharge of the patient unless there is a strong suspicion of
perforated peptic ulcer, usually because of features of peritonitis
or because pain control could not be achieved. In such instances,
either a plain X-ray of the abdomen or emergency CT scan, or
both may be performed to identify the presence of free-intraperi-
toneal gas (Ghekiere 2007; Grassi 2004). The usual treatment for
perforated peptic ulcer is emergency surgical closure, which can
be performed by open or laparoscopic surgery (Sanabria 2013).
If a diagnosis of acute pancreatitis can be established, usually based
on the consensus criteria, the patient is admitted to hospital and
the severity of pancreatitis is assessed. The treatment of acute pan-
creatitis is generally supportive treatment, that is maintenance of
fluid and electrolyte imbalance. Despite various pharmacologi-
cal interventions being evaluated in acute pancreatitis, none is
currently recommended as treatment. Abdominal ultrasound and
magnetic resonance cholangiopancreatography or endoscopic ul-
trasound may be performed to investigate the aetiology of acute
pancreatitis. In the presence of gallstones, cholecystectomy is per-
formed. The timing of cholecystectomy in acute pancreatitis is
controversial, and different factors must be considered depend-
ing upon the severity of acute pancreatitis (Gurusamy 2013). En-
doscopic sphincterotomy or common bile duct exploration may
have to be performed in the presence of common bile duct stones
(Ayub 2004; Larson 2006). In the absence of gallstones, investi-
gation of other causes of acute pancreatitis is required. Patients
are generally monitored clinically. If the patient improves clini-
cally with supportive treatment, the patient with gallstone pan-
creatitis is discharged after cholecystectomy or after scheduling a
cholecystectomy or on a planned list, within two weeks. For those
patients with severe acute pancreatitis, cholecystectomy is under-
taken when clinically appropriate after resolution of pancreatitis.
If the patient deteriorates clinically, the patient undergoes a CT
scan and may require high-dependency or intensive care in the
presence of organ failure or infected pancreatic necrosis.
In the presence of organ failure, patients undergo a CT scan or
MRI to identify any local complications. C-reactive protein, pro-
calcitonin, and lactate dehydrogenase might distinguish between
oedematous and necrotising pancreatitis (Alfonso 2003; Khanna
2013; Rau 1998), and could potentially be used as a triage test
to identify patients who need further radiological tests in those
without organ failure (Alfonso 2003). Some centres use C-reac-
tive protein routinely to determine whether patients require ra-
diological investigations to diagnose necrotising pancreatitis. Fre-
quently, the rising trend in C-reactive protein, procalcitonin, or
lactate dehydrogenase, rather than a single test, may be used to
determine whether patients require radiological investigations to
diagnose necrotising pancreatitis. It must be noted that CT scan
or MRI is not routinely performed during the initial stages of
acute pancreatitis, but usually in the presence of organ failure or
because of the results of the serum C-reactive protein. The various
treatment strategies for acute necrotising pancreatitis include non-
surgical (conservative) treatment, percutaneous drainage, endo-
scopic transluminal drainage, early surgical debridement (necro-
sectomy, which can be performed by open surgery or by min-
imally invasive retroperitoneal debridement), delayed necrosec-
tomy (delaying the surgery by about four weeks), or a step-up ap-
proach that consists of endoscopic or percutaneous drainage fol-
lowed by laparoscopic necrosectomy if required, and non-surgi-
cal (conservative) treatment (Bakker 2012; Mouli 2013; Tenner
2013; van Brunschot 2014; van Santvoort 2010; van Santvoort
2011). A recent Cochrane systematic review found that a step-up
approach may be preferable to direct surgery in participants with
acute necrotising pancreatitis (Gurusamy 2016). All of these treat-
ments are supported by appropriate fluid therapy and nutritional
support. This is in comparison with severe acute oedematous pan-
creatitis, where themain treatment is supportive treatment for sys-
temic complications, including organ failure and treatment of local
complications such as pseudocyst if symptomatic (Cannon 2009;
Cheruvu 2003; Johnson 2009; Varadarajulu 2008; Varadarajulu
2013). If patients have infected pancreatic necrosis, appropriate
antibiotics are administered in addition to the treatment outlined
above for non-infected pancreatic necrosis. If patients have acute
peripancreatic collections or pseudocysts on the radiological tests,
clinical and radiological follow-up are required to ensure resolu-
tion of these collections.
If the diagnosis of acute pancreatitis cannot be ruled out on the ba-
sis of the clinical presentation and serum amylase or lipase, the pa-
tient is admitted to hospital and the evolution of signs and symp-
toms is noted. Serum amylase and lipase may be repeated or radi-
ological examinations may be performed to establish or rule out
acute pancreatitis with a reasonable amount of certainty. Tests for
organ failure (e.g. urea and creatinine for identifying renal failure,
blood pressure, pulse rate, respiratory rate, urine output, and arte-
rial blood gases) may also be performed to ensure that the patient
does not have moderately severe or severe pancreatitis irrespective
of the results of serum amylase and lipase. The possible clinical
pathway in the diagnosis and management of acute pancreatitis is
shown in Figure 1.
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Figure 1. Clinical pathway.Footnotes:Acute pancreatitis is usually confirmed by consensus criteria (Banks
2013).Irrespective of the CT scan findings and presence or absence of necrosis, patients with organ failure will
require organ support and will receive a CT scan.CT scan may also be performed in people without organ
failure if there is clinical deterioration (not amounting to organ failure) or in some centres based on an
elevated CRP.Necrotising pancreatitis is usually confirmed by the findings on the CT scan and by
histopathological examination of the biopsy obtained during necrosectomy if early necrosectomy is
performed.Infected necrotising pancreatitis is usually confirmed by the findings on the CT scan and by
microbiological examination of fluid aspirated under radiological guidance or from the tissue biopsy obtained
during necrosectomy if early necrosectomy is performed.Organ failure is diagnosed on the basis of clinical
examination and blood tests (urea, creatinine, blood pressure, pulse rate, respiratory rate, arterial blood gas
analysis).Abbreviations:CRP: C-reactive proteinCT: computed tomographyEUS: endoscopic ultrasoundMRCP:
magnetic resonance cholangiopancreatography
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Prior test(s)
The minimum prior test that is performed before these tests are
conducted is clinical history and clinical examination, which in-
cludes obtaining the body temperature, heart rate, blood pressure,
respiratory rate, and pulse oximetry (when available).
Role of index test(s)
The index tests are used for the diagnosis of acute pancreatitis in
people with acute onset of a persistent, severe epigastric pain or
with diffuse abdominal pain that started in the epigastric region
(or if the person is unsure about the region in which diffuse ab-
dominal pain began). The current tests used are serum amylase
and serum lipase. Urinary trypsinogen and urinary amylase are
being evaluated as replacement tests for serum amylase and serum
lipase.
Alternative test(s)
Other tests used in the diagnosis of acute pancreatitis include
serum trypsinogen-2 (Hedstrom 1994), and radiological tests such
as contrast-enhanced computed tomography (CECT), magnetic
resonance imaging (MRI), or transabdominal ultrasonography
(Banks 2013). Other biomarkers such as serum trypsin-2-alpha1-
antitrypsin complex, carboxypeptidase B activation peptide (CA-
PAP), and urinary trypsinogen activation peptide (TAP) have
been evaluated as diagnostic tests for acute pancreatitis (Hedstrom
1996d; Saez 2005), but these are not in routine use for the diag-
nosis of this condition.
Rationale
In addition to acute pancreatitis, there are several other causes of
epigastric pain including peptic ulcer, functional dyspepsia, and
gallstones (Gurusamy 2014; Moayyedi 2006). Of these various
causes, people with acute pancreatitis and perforated peptic ulcer
need emergency admission and treatment, while others may be
discharged if pain control can be achieved. It is thus important
to make a diagnosis of acute pancreatitis. Radiological findings
of acute pancreatitis evolve over a few days, and the radiological
examination may not demonstrate characteristic features in the
early stages, or may even be normal (Banks 2013; Vissers 1999),
thus radiological tests are not routinely performed for diagnosing
this condition. In addition, acute pancreatitis can mimic perfo-
rated peptic ulcer (Kuzmich 2012), which is usually treated by
surgery. Correct diagnosis of acute pancreatitis can avoid unneces-
sary surgery. Hence, an accurate diagnostic test for the diagnosis of
acute pancreatitis is essential in people with suspected acute pan-
creatitis. Serum amylase and lipase are the tests most commonly
used in the diagnosis of acute pancreatitis. It is important to un-
derstand the diagnostic accuracy of these tests. Urinary trypsino-
gen and amylase have been investigated as alternate tests, and it is
important to understand whether they can replace serum amylase
and lipase in the diagnosis of acute pancreatitis. If one or more of
the tests being assessed has a high degree of accuracy, patients with
acute pancreatitis can be identified and managed appropriately.
At the same time, unnecessary hospital admission for observation
can be avoided in patients without acute pancreatitis, resulting in
considerable resource savings. There has been no systematic review
and meta-analysis of the diagnostic accuracy of serum lipase and
amylase activity or urinary amylase in the diagnosis of acute pan-
creatitis. The current consensus criteria about diagnosis of acute
pancreatitis included serum lipase or amylase activity at least three
times greater than the upper limit of normal as one of the cri-
teria for diagnosis of acute pancreatitis (two of the three criteria
must be met, the other two being acute abdominal pain and imag-
ing characteristic of acute pancreatitis) (Banks 2013). However,
these criteria are based on consensus rather than on systematic
reviews. In addition, the threshold for amylase or lipase may need
to be revised from three times normal to a different threshold if
these tests are accurate at different thresholds. If this systematic
review found that urinary amylase or trypsinogen-2 were better
than serum amylase or lipase, the criteria for the diagnosis of acute
pancreatitis would need to be altered. There have been two system-
atic reviews on the diagnostic test accuracy of urinary trypsinogen-
2 in the diagnosis of acute pancreatitis (Chang 2012; Jin 2013).
In both reviews, language restrictions (English and Chinese) were
present. The searches were performed in 2011 and 2012, respec-
tively. Only one of the reviews used appropriate statistical analysis
(Chang 2012). There has been no Cochrane review on the role of
urinary trypsinogen-2 in the diagnosis of acute pancreatitis. The
change in diagnostic accuracy of these tests with different time
intervals from presentation has not been previously assessed in a
systematic review. A Cochrane systematic review of the diagnostic
test accuracy of serum and urine tests in the diagnosis of acute
pancreatitis was, therefore, necessary.
O B J E C T I V E S
To compare the diagnostic accuracy of serum amylase, serum li-
pase, urinary trypsinogen-2, and urinary amylase, either alone or
in combination, in the diagnosis of acute pancreatitis in people
with acute onset of a persistent, severe epigastric pain or diffuse
abdominal pain.
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Secondary objectives
We planned to explore the following sources of heterogeneity.
• Studies at low risk of bias in all of the domains versus those
at unclear or high risk of bias (as assessed by the Quality
Assessment of Diagnostic Accuracy Studies (QUADAS-2) tool,
recommended by the Cochrane Diagnostic Test Accuracy
Group) (Whiting 2006; Whiting 2011).
• Prospective studies versus retrospective studies (to
determine whether there is a difference in diagnostic accuracy
between prospective and retrospective studies).
• Full-text publications versus abstracts (this can be indicative
of publication bias since there may be an association between the
results of the study and the study reaching full publication
status) (Eloubeidi 2001).
• Previous history of acute pancreatitis.
• Different aetiology for acute pancreatitis (gallstone versus
alcohol versus other aetiology). The accuracy of the test may
depend upon the aetiology of the acute pancreatitis.
• Presence of organ failure. The accuracy of the test may
depend upon the presence of organ failure.
• Average time to performance of the test. The accuracy of
the test may depend upon the interval between the onset of
clinical symptoms and the performance of the test.
• Different test manufacturers.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included studies that evaluated the accuracy of the index tests
mentioned above in the appropriate patient population (see be-
low).We included relevant studies irrespective of language or pub-
lication status (i.e. published as full text or abstract), whether the
data were collected prospectively or retrospectively, and whether
there was a comparison between the tests. However, we excluded
case reports (which describe how the diagnosis of acute pancreati-
tis was made on an individual patient or a group of patients and
which do not provide sufficient diagnostic test accuracy data, i.e.
true positive, false positive, false negative, and true negative). We
also excluded case-control studies because they are prone to bias
(Whiting 2011).
Participants
Adults with acute epigastric or diffuse abdominal pain (with or
without previous history of acute pancreatitis and with or without
systemic signs and symptoms of acute pancreatitis), presenting to
the hospital within three days of the onset of symptoms, irrespec-
tive of the interval between onset of symptoms and the time at
which the test was performed.
Index tests
Serum amylase, serum lipase, urinary trypsinogen, and urinary
amylase either alone or in combination. A variety of kits are avail-
able for measuring these tests. We included kits from all manu-
facturers, and included studies irrespective of the threshold used.
Although we did not plan to include repeat tests, the diagnostic
test accuracy of these index tests on later days might give some
indication of the performance of these tests in patients with a pro-
longed period of symptoms before going to the hospital. We have
therefore analysed and reported this information separately from
the tests conducted on admission.
Target conditions
Acute pancreatitis (regardless of severity: mild, moderately severe,
or severe)
Reference standards
While inflammation of the pancreas confirmed by biopsy can be
considered to be the gold standard for the diagnosis of acute pan-
creatitis, for ethical reasons it is unlikely to be performed in any
participant. As a result, different study authors may use different
reference standards such as radiological features of acute pancre-
atitis or the presence of organ failure. However, such reference
standards may miss some cases of mild acute pancreatitis, which
will result in an underestimation of diagnostic test accuracy of the
index tests. We also accepted the consensus conference definition
of acute pancreatitis, that is when at least two of the following
three features are present (Banks 2013).
• Acute onset of a persistent, severe epigastric pain often
radiating to the back.
• Serum lipase activity (or amylase activity) at least three
times greater than the upper limit of normal.
• Characteristic findings of acute pancreatitis on CECT, and
less commonly on MRI or transabdominal ultrasonography.
We also accepted any of the following reference standards, used
alone or in combination: biopsy, radiological features of acute pan-
creatitis (CT or MRI), diagnosis of acute pancreatitis during la-
parotomy or autopsy, organ failure, or the consensus conference
definition (including or excluding the index test being evaluated).
In terms of ranking the reference standards, we considered biopsy
to be the best reference standard (although for ethical reasons it
is unlikely to have been performed in any participant) followed
by the consensus definition of acute pancreatitis; radiological, la-
parotomy, or autopsy features of acute pancreatitis; or the presence
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of organ failure, in that order. However, we anticipated that the
authors would exclude the test being assessed to be incorporated
into the reference standard. For example, if serum amylase was
being evaluated, the final diagnosis of acute pancreatitis would not
depend upon the levels of serum amylase; this was not the case, as
described below. If the test being assessed was incorporated into
the reference standard, the diagnostic accuracy of the test would
be overestimated.
Search methods for identification of studies
We included all studies irrespective of the language of publication
and publication status. We obtained translations for non-English
language articles.
Electronic searches
We searched the following databases.
1. MEDLINE (In-Process & Other Non-Indexed Citations
and Ovid MEDLINE(R)) via OvidSP (January 1946 to 20
March 2017) (Appendix 2).
2. Embase via OvidSP (January 1947 to 20 March 2017)
(Appendix 3).
3. Science Citation Index Expanded via Web of Knowledge
(January 1980 to 20 March 2017) (Appendix 4).
4. Conference Proceedings Citation Index-Science (CPCI-S)
via Web of Knowledge (January 1990 to 20 March 2017)
(Appendix 4).
5. National Insitute for Health Research (NIHR HTA and
DARE) via Centre for Reviews and Dissemination (20 March
2017) (Appendix 5).
6. Zetoc via British Library (20 March 2017) (Appendix 6).
7. World Health Organization (WHO) International Clinical
Trials Registry Platform (ICTRP) (www.who.int/ictrp/en/) (20
March 2017) (Appendix 7).
8. ClinicalTrials.gov (clinicaltrials.gov/) (20 March 2017)
(Appendix 8).
Weused the same strategy for this review and another reviewon the
diagnosis of pancreatic necrosis in people with established acute
pancreatitis (Gurusamy 2015).
Searching other resources
We searched the references of the included studies to identify addi-
tional studies. We also searched for articles related to the included
studies by performing the ’related search’ function in MEDLINE
(OvidSP) and Embase (OvidSP) and a ’citing reference’ search
(by searching the articles that cite the included articles) in these
databases (Sampson 2008).
Data collection and analysis
Selection of studies
Two review authors (KSG and OK) independently searched the
references to identify relevant studies. We obtained the full texts
of references considered to be relevant by at least one of the review
authors. Two review authors (KSG and GR or AH) independently
screened the full-text papers against the inclusion criteria. Any
disagreements in study selection were resolved by discussion. We
planned to contact the study authors if there were any doubts
about study eligibility.
Data extraction and management
Two review authors (KSGandGRorAH) independently extracted
the following data from each included study using a data extraction
form designed and piloted by KSG. Any differences were resolved
by discussion.
1. First author.
2. Year of publication.
3. Study design (prospective or retrospective cohort studies;
cross-sectional studies or randomised controlled trials).
4. Inclusion and exclusion criteria for individual studies.
5. Total number of participants.
6. Number of females.
7. Average age of the participants.
8. Average time between onset of symptoms and index test.
9. Aetiology of acute pancreatitis.
10. Proportion of participants with organ failure.
11. Description of the index test.
12. Threshold used for index test.
13. Reference standard.
14. Number of true positives, false positives, false negatives,
and true negatives.
If the same study reported multiple index tests, we extracted the
number of true positives, false positives, false negatives, and true
negatives for each index test at each threshold. If the same study
reported the number of true positives, false positives, false nega-
tives, and true negatives for each index test at different thresholds,
we extracted this information for each threshold. If the study re-
ported the results for a combination of tests, we planned to extract
the number of true positives, false positives, false negatives, and
true negatives for each different combination of tests.
We defined a combination of tests as positive in two ways: ’at
least one test positive’ or ’all tests positive’. We planned to extract
the number of true positives, false positives, false negatives, and
true negatives for both the scenarios. If the study reported the
test at multiple time points, we planned to use the results of the
first test in the diagnosis of acute pancreatitis to calculate the true
positives, false positives, false negatives, and true negatives, since
the aim of this review was to assess the diagnostic accuracy in
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peoplewith acute epigastric pain and abdominal painwhohave not
undergone any prior tests other than routine clinical examination.
However, the diagnostic test accuracy of these index tests on later
days of hospital might give some indication on the performance of
these tests in patients with a prolonged period of symptoms before
going to hospital. We have therefore analysed and reported this
information separately from the tests conducted on admission.
We planned to exclude patients with uninterpretable index test
results (whatever the reason given for lack of interpretation), since
in clinical practice, uninterpretable index test results will result in
additional tests for the diagnosis of acute pancreatitis. However,
we planned to record the number of uninterpretable index test
results, as this would provide information on the applicability of
the test in clinical practice and may affect the cost-effectiveness
of a test. (Although cost-effectiveness is outside the scope of this
review, cost-effectiveness studies may use data from this review).
If there was an overlap of participants between multiple reports, as
suggested by common authors and centres, we planned to contact
the study authors to seek clarification about the overlap. If we were
unable to contact the authors, we planned to extract themaximum
possible information from all of the reports. We sought further
information from study authors where necessary.
Assessment of methodological quality
Two review authors (KSG and GR or AH) independently assessed
study quality using the QUADAS-2 assessment tool (Whiting
2006; Whiting 2011). We resolved any differences by discussion
and using the criteria to classify the different studies published
in the protocol and available in Table 2. We considered studies
classified as ’low risk of bias’ and ’low concern’ in all of the domains
as studies with high methodological quality. We have presented
the results in a ’Risk of bias’ summary and graphs in addition to a
narrative summary.
Statistical analysis and data synthesis
We have reported the reference standards in each study included
in the analysis and have analysed the studies at different thresh-
old levels separately. We plotted study estimates of sensitivity and
specificity on forest plots and in receiver operating characteris-
tic (ROC) space to explore between-study variation in the per-
formance of each test stratified by the threshold. To estimate the
summary sensitivity and specificity of each test at each threshold
level, we attempted to perform the meta-analysis by fitting the
bivariate model (Chu 2006; Reitsma 2005). This model accounts
for between-study variability in estimates of sensitivity and speci-
ficity through the inclusion of random effects for the logit sensi-
tivity and logit specificity parameters of the bivariate model. How-
ever, because of sparse data, we used simpler models described
by Takwoingi 2015 (random-effects model ignoring the inverse
correlation between sensitivities and specificities in the different
studies due to intrinsic threshold effect, and the fixed-effect model
for either sensitivity or specificity, or both). We based the choice
between the different models on the -2 log likelihood ratio and the
distribution of sensitivities and specificities as noted in the forest
plots or ROC space (Takwoingi 2015).
We performed the meta-analysis using the NLMIXED command
in SAS version 9.4 (SAS Institute Inc, Cary, NC, USA).We calcu-
lated the summary likelihood ratios and their confidence intervals
from the functions of the parameter estimates from the bivariate
model or other models that were fitted to estimate the summary
sensitivities and specificities. We calculated the post-test proba-
bility using the median pre-test probability. Post-test probability
associated with a positive test is the probability of having the target
condition (acute pancreatitis) on the basis of a positive test result,
and is the same as the term ’positive predictive value’ used in a
single diagnostic accuracy study. Post-test probability associated
with a negative test is the probability of having the target condition
(acute pancreatitis) on the basis of a negative test result and is 1
- ’negative predictive value’. Negative predictive value is the term
used in a single diagnostic accuracy study to indicate the chance
that the patient has no target condition when the test is negative.
Investigations of heterogeneity
Of the eight sources of heterogeneity mentioned in the Secondary
objectives section, we planned to use risk of bias, publication sta-
tus, prospective or retrospective studies, and different test manu-
facturers as categorical covariates, and proportion of participants
with a previous history of acute pancreatitis, proportion of partic-
ipants with different aetiologies, proportion of participants with
organ failure, and the average time to performance of the test as
continuous covariates in the regression model. We planned to in-
clude one covariate at a time in the regression model. We planned
to use the likelihood ratio test to determine whether the covari-
ate was statistically significant. However, because of the paucity of
data, we did not perform any of the above analyses.
Sensitivity analyses
We did not plan any sensitivity analyses except when the data
available from the studies were ambiguous (e.g. the numbers in
the text differed from the numbers in the figures), in which case
we planned to assess the impact of different data used by a sensi-
tivity analysis. However, we performed three post hoc sensitivity
analyses.
• There was incorporation bias (index test was a part of the
reference standard) in many of the studies that reported on the
diagnostic accuracy of serum amylase and lipase. We performed a
sensitivity analysis by excluding these studies.
• There was high risk of bias and applicability concerns in
one retrospective study that contributed to most of the effect
estimate (Chang 2011). We performed a sensitivity analysis by
excluding this study.
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• For urinary trypsinogen-2, the authors of one study
appeared to have used the threshold suggested by the
manufacturer (Aysan 2008); however, this was not stated clearly.
We performed a sensitivity analysis by excluding this study.
Assessment of reporting bias
We planned to investigate whether the summary sensitivity and
specificity differed between studies published as full texts and those
that were available only as abstracts (at least two years prior to
the search date) using the methods described in the Investigations
of heterogeneity section. We did not perform this since all of the
included studies were full texts.
R E S U L T S
Results of the search
We identified a total of 23,660 references through the electronic
searches of MEDLINE (n = 7326), Embase (n = 11,502), Science
Citation Index Expanded (n = 4293),National Institute forHealth
Research (NIHR HTA and DARE) (n = 142), Zetoc (n = 360),
WHO ICTRP (n = 1), and ClinicalTrials.gov (n = 36). We ex-
cluded 10,657 duplicates and 12,547 clearly irrelevant references
through reading the titles or abstracts, or both. We sought full-
text articles for 456 references, but were unable to obtain the full
texts for six references (Anand 1956; Cherry 1953; Coppola 1954;
Do Prado 1952; Lippi 2013; Stimac 1995). We retrieved full-text
articles of 450 references for further assessment against our review
protocol inclusion criteria. Of these 450 references, we excluded
440 references for the reasons provided in the Characteristics of
excluded studies section. The reasons for exclusion were: case-
control study: 102; inappropriate population: 195; inappropriate
reference standard: 48; inappropriate target condition: 2; no di-
agnostic test accuracy data: 33; not a primary research study: 60;
could not be obtained: 6. Ten studies (10 references) fulfilled the
inclusion criteria and provided the diagnostic accuracy data for the
review (Abraham 2011; Aysan 2008; Burkitt 1987; Chang 2011;
Keim 1998; Mayumi 2012; Patt 1966; Saez 2005; Viel 1990; Wu
2009). We have shown the reference flow in Figure 2.
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Figure 2. Study flow diagram.
12Serum amylase and lipase and urinary trypsinogen and amylase for diagnosis of acute pancreatitis (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Included studies
Ten studies including 5056 participants met the inclusion criteria
for this review and assessed the diagnostic accuracy of the index
tests in people presenting to the hospital emergency department
with acute abdominal pain. The average age of participants in
the studies ranged from 37 years to 59 years in the five studies
that reported this information (Aysan 2008; Keim 1998; Mayumi
2012; Saez 2005; Wu 2009). About 45% of participants (442/
970 participants) were females in the five studies that reported
this information (Aysan 2008; Keim 1998; Mayumi 2012; Saez
2005; Wu 2009). Six studies were prospective studies (Abraham
2011; Aysan 2008; Burkitt 1987; Keim1998;Mayumi 2012; Saez
2005); one study was a retrospective study (Chang 2011); and it
was unclear whether three studies were prospective or retrospec-
tive (Patt 1966; Viel 1990; Wu 2009). All of the included studies
were full-text publications. The studies did not report whether
people with previous history of acute pancreatitis were included.
Two studies clearly stated that they included patients with gall-
stone pancreatitis and alcoholic pancreatitis (Mayumi 2012; Saez
2005). None of the studies reported any restriction of inclusion
criteria based on aetiology or provided diagnostic accuracy infor-
mation separately for people with gallstone and alcoholic pancre-
atitis. None of the studies included only people with organ failure
or excluded all people with organ failure. One study excluded peo-
ple with renal failure, but there was no restriction on the basis of
other organ failures (Chang 2011). None of the studies reported
data separately for people with and without organ failure. Only
one study reported that they included only people with less than
24 hours since onset of symptoms (Saez 2005). None of the other
trials restricted participants based on the duration of symptoms.
However, since all of the studies included participants with acute
abdominal pain, it is likely that the onset of pain was less than two
to three days prior to hospital admission.
The studies measured the diagnostic accuracy on admission and
used different thresholds for diagnosis of acute pancreatitis. Eight
studies contributed to two or more analyses (Abraham 2011;
Burkitt 1987; Chang 2011; Keim1998;Mayumi 2012; Patt 1966;
Saez 2005; Wu 2009). However, none of the studies reported the
diagnostic accuracy of a combination of tests.
Methodological quality of included studies
The methodological quality of the included studies is shown in
Characteristics of included studies, and summaries of themethod-
ological quality are shown in Figure 3 and Figure 4.
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Figure 3. Risk of bias and applicability concerns summary: review authors’ judgements about each domain
for each included study.
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Figure 4. Risk of bias and applicability concerns graph: review authors’ judgements about each domain
presented as percentages across included studies.
Participant selection
A total of four studies were at low risk of bias in the participant
selection domain (Abraham 2011;Mayumi 2012; Saez 2005; Viel
1990). A total of three studies were at high risk of bias in the par-
ticipant selection domain (Burkitt 1987; Chang 2011; Patt 1966).
In one study, some participants who had normal urinary amy-
lase were excluded from analysis (Burkitt 1987); in another study,
participants with parotid disease and end-stage renal failure were
excluded (Chang 2011); and in a third study, only participants
who underwent laparotomy or autopsy were included, that is only
people with severe symptoms were included (Patt 1966). A total of
three studies were at unclear risk of bias in the participant selection
domain (Aysan 2008; Keim 1998; Wu 2009).
There was low concern in the participant selection domain in four
studies (Abraham 2011; Mayumi 2012; Saez 2005; Viel 1990).
There was high concern in the participant selection domain in
three studies (Burkitt 1987; Chang 2011; Patt 1966). The rea-
sons for high concern were the same as those for high risk of bias
(Burkitt 1987). There was unclear concern in the participant selec-
tion domain in three studies (Aysan 2008; Keim 1998;Wu 2009).
Index test
One study was at low risk of bias for all index tests other than
one threshold (urinary trypsinogen positive or most positive) (
Mayumi 2012); for that threshold the study was at high risk of
bias since the threshold was not prespecified (Mayumi 2012). One
study was at high risk of bias for all index tests since the threshold
was not prespecified (Keim 1998). The remaining trials were at
unclear risk of bias since it was not clear whether the threshold
was prespecified and whether blinded interpretation of the index
tests was performed (Abraham 2011; Aysan 2008; Burkitt 1987;
Chang 2011; Patt 1966; Saez 2005; Viel 1990; Wu 2009). All of
the index tests reported in eight studies were at low concern about
applicability (Abraham 2011; Burkitt 1987; Chang 2011; Keim
1998; Patt 1966; Saez 2005; Viel 1990; Wu 2009). One study
was at unclear concern about applicability since the threshold used
was not clearly reported by the authors (the authors appear to
have used the manufacturer’s suggested threshold, but this was
not entirely clear) (Aysan 2008). One study was at high concern
about applicability for all index tests except for one threshold level
(positive or most positive), since this is not a standard threshold
recommended by the manufacturer (Mayumi 2012).
Reference standard
Five studies were at high risk of bias in the reference standard
domain because they did not use a biopsy or consensus definition
(Aysan 2008; Chang 2011; Keim 1998; Viel 1990; Wu 2009).
One of these studies also included the index test as part of the
reference standard despite not using consensus definition (Wu
2009). Five studies were at unclear risk of bias about the reference
standard since they did not report whether the people interpreting
the reference standards were blinded to the index test results (
Abraham 2011; Burkitt 1987; Mayumi 2012; Patt 1966; Saez
2005). However, it should be noted that three studies were at high
risk of bias for the index tests serum amylase and serum lipase,
which were part of the reference standards, but were at low risk
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of bias for urinary trypsinogen-2 (Abraham 2011; Mayumi 2012;
Saez 2005). As we included only studies in which the reference
standard was adequately described, the applicability concern was
low in all studies.
Flow and timing
All of the studies were at unclear risk of bias in the flow and
timing domain since the studies either did not report whether
any participants with uninterpretable results were excluded or did
not state the time interval between the index test and reference
standard.
Findings
The included studies reported the diagnostic test accuracy of the
different tests in the diagnosis of acute pancreatitis at different test
thresholds and on different days. Due to sparse data, we performed
the meta-analysis using different models described by Takwoingi
2015. The data and the SAS code used are shown in Appendix
9. The model fit (-2 log likelihood ratios) for various analyses is
reported in Appendix 10. Themedian pre-test probability of acute
pancreatitis (proportion of people with acute pancreatitis out of
the total number of included participants) was 22.6% with a min-
imum of 0.6% and a maximum of 69.4%. The lower and upper
quartiles were 16.3% and 47.3%, respectively. The sensitivity and
specificity along with the 95% confidence interval (CI) for each of
the main analyses are shown in a forest plot (Figure 5) and ROC
space (Figure 6). The sensitivities, specificities, post-test proba-
bilities of a positive test, and post-test probabilities of a negative
test at the median pre-test probability for the main analyses are
presented in the Summary of findings and for all of the tests are
presented in Table 3, Table 4, and Table 5.
Figure 5. Forest plot of serum amylase, serum lipase, and urinary trypsinogen at different thresholds. There
was reasonable overlap of 95% confidence intervals except specificity for serum amylase > 3 times normal,
sensitivity and specificity of serum lipase > 3 times normal, and specificity of urinary trypsinogen-2.
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Figure 6. Summary estimates and 95% confidence region (ellipses) of the three main meta-analyses
showing similar diagnostic test accuracies. No confidence regions could be computed for serum amylase due
to small numbers of studies.
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Serum amylase
More than three times normal on admission
A total of four studies (4056 participants) were included in this
analysis (Abraham 2011; Chang 2011;Mayumi 2012; Saez 2005).
It should be noted that except for Chang 2011, all of the studies
suffered from incorporation bias (i.e. index test was part of refer-
ence standard). Based on the -2 log likelihood ratio, fixed-effect
model for both sensitivity and specificity was used for meta-anal-
ysis. The summary estimate of sensitivity for diagnosis of acute
pancreatitis was 0.71 (95% CI 0.65 to 0.77) and the summary
estimate of specificity for diagnosis of acute pancreatitis was 0.99
(95% CI 0.99 to 0.99).
Excluding three studies with incorporation bias, Abraham 2011,
Mayumi 2012, and Saez 2005 (studies that used consensus defi-
nition as the reference standard) resulted in the inclusion of only
Chang 2011, which used radiology as the reference standard. The
estimate of sensitivity for diagnosis of acute pancreatitis was 0.64
(95% CI 0.41 to 0.82) and the estimate of specificity for diagnosis
of acute pancreatitis was 0.99 (95% CI 0.99 to 1.00).
Excluding Chang 2011, for which there was major concern about
applicability, resulted in the inclusion of a total of three studies
(605 participants) (Abraham 2011; Mayumi 2012; Saez 2005).
Based on the -2 log likelihood ratio, the fixed-effect model for
sensitivity and random-effects model for specificity were used for
meta-analysis. The summary estimate of sensitivity for diagnosis
of acute pancreatitis was 0.72 (95% CI 0.59 to 0.82) and the
summary estimate of specificity for diagnosis of acute pancreatitis
was 0.93 (95% CI 0.66 to 0.99).
More than twice normal
On admission
A total of two studies (3704 participants) were included in this
analysis (Chang 2011; Keim 1998). There was no incorporation
bias in either study, as both studies used radiology as a reference
standard. Based on the -2 log likelihood ratio, fixed-effect model
for both sensitivity and specificity was used for meta-analysis. The
summary estimate of sensitivity for diagnosis of acute pancreatitis
was 0.76 (95% CI 0.57 to 0.88) and the summary estimate of
specificity for diagnosis of acute pancreatitis was 0.99 (95% CI
0.98 to 0.99). Excluding Chang 2011, for which there was major
concern about applicability, resulted in the inclusion of one study
(253 participants) in this analysis (Keim 1998). The estimate of
sensitivity for diagnosis of acute pancreatitis was 0.72 (95% CI
0.53 to 0.86) and the estimate of specificity for diagnosis of acute
pancreatitis was 0.98 (95% CI 0.95 to 0.99).
Two to three days after admission
One study (253 participants) was included in this analysis (Keim
1998). There was no incorporation bias in this study as this study
used radiology as a reference standard. The estimate of sensitivity
for diagnosis of acute pancreatitis was 0.25 (95% CI 0.12 to 0.44)
and the estimate of specificity for diagnosis of acute pancreatitis
was 0.97 (95% CI 0.93 to 0.99).
Four to five days after admission
One study (253 participants) was included in this analysis (Keim
1998). There was no incorporation bias in this study as this study
used radiology as a reference standard. The estimate of sensitivity
for diagnosis of acute pancreatitis was 0.06 (95% CI 0.01 to 0.22)
and the estimate of specificity for diagnosis of acute pancreatitis
was 0.93 (95% CI 0.89 to 0.96).
More than normal
On admission
A total of three studies (587 participants) were included in this
analysis (Keim 1998; Patt 1966; Wu 2009). There was no incor-
poration bias in two studies: Keim 1998 used radiology and Patt
1966 used laparotomy or autopsy as the reference standard. Based
on the -2 log likelihood ratio, fixed-effect model for both sen-
sitivity and specificity was used for meta-analysis. The summary
estimate of sensitivity for diagnosis of acute pancreatitis was 0.88
(95%CI 0.77 to 0.94) and the summary estimate of specificity for
diagnosis of acute pancreatitis was 0.88 (95% CI 0.84 to 0.91).
ExcludingWu 2009, a study that had incorporation bias (although
the authors did not use the consensus definition, they used a com-
bination of pain, radiology, and raised amylase), resulted in a sum-
mary sensitivity and specificity for diagnosis of acute pancreatitis
of 0.89 (95% CI 0.72 to 0.96) and 0.88 (95% CI 0.83 to 0.92),
respectively. This was based on fixed-effect model for both sensi-
tivity and specificity, the only model that converged.
Two to three days after admission
One study (253 participants) was included in this analysis (Keim
1998). There was no incorporation bias in this study, as this study
used radiology as the reference standard.The estimate of sensitivity
for diagnosis of acute pancreatitis was 0.66 (95% CI 0.47 to 0.81)
and the estimate of specificity for diagnosis of acute pancreatitis
was 0.83 (95% CI 0.77 to 0.87).
18Serum amylase and lipase and urinary trypsinogen and amylase for diagnosis of acute pancreatitis (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Four to five days after admission
One study (253 participants) was included in this analysis (Keim
1998). There was no incorporation bias in this study, as this study
used radiology as the reference standard.The estimate of sensitivity
for diagnosis of acute pancreatitis was 0.34 (95% CI 0.19 to 0.53)
and the estimate of specificity for diagnosis of acute pancreatitis
was 0.86 (95% CI 0.81 to 0.90).
Serum lipase
More than three times normal on admission
A total of five studies (4129 participants) were included in this
analysis (Abraham 2011; Chang 2011; Mayumi 2012; Saez 2005;
Viel 1990). Of these, there was no incorporation bias in two stud-
ies: Chang 2011 used radiology as the reference standard, while
Viel 1990 used 3-fold increase of serum amylase and evidence of
pancreatitis in radiology, endoscopic retrograde cholangiopancre-
atography (ERCP), or surgery as the reference standard. Based on
the -2 log likelihood ratio, fixed-effect model for sensitivity and
random-effects model for specificity were used for meta-analysis.
The summary estimate of sensitivity for diagnosis of acute pancre-
atitis was 0.80 (95% CI 0.73 to 0.86) and the summary estimate
of specificity for diagnosis of acute pancreatitis was 0.93 (95% CI
0.00 to 1.00).
Excluding three studies with incorporation bias (these studies used
consensus definition as the reference standard) (Abraham 2011;
Mayumi 2012; Saez 2005), the summary estimate of sensitivity
for diagnosis of acute pancreatitis was 0.88 (95% CI 0.02 to 1.00)
and the summary estimate of specificity for diagnosis of acute pan-
creatitis was 0.94 (95% CI 0.00 to 1.00). Only two models, fixed-
effect model for sensitivity and random-effects model for speci-
ficity and fixed-effect models for both sensitivity and specificity,
converged. Based on the -2 log likelihood ratio, fixed-effect model
for sensitivity and random-effects model for specificity were used
for meta-analysis.
Excluding Chang 2011, for which there was major concern about
applicability, resulted in the inclusion of four studies (678 partici-
pants) in this analysis (Abraham 2011; Mayumi 2012; Saez 2005;
Viel 1990). Based on the -2 log likelihood ratio, random-effects
model for both sensitivity and specificity was used for meta-anal-
ysis. The summary estimate of sensitivity for diagnosis of acute
pancreatitis was 0.79 (95% CI 0.54 to 0.92) and the summary
estimate of specificity for diagnosis of acute pancreatitis was 0.89
(95% CI 0.46 to 0.99).
More than twice normal
On admission
A total of two studies (3704 participants) were included in this
analysis (Chang 2011; Keim 1998). There was no incorporation
bias in either study, as both studies used radiology as the reference
standard. Based on the -2 log likelihood ratio, fixed-effect model
for both sensitivity and specificity was used for meta-analysis. The
summary estimate of sensitivity for diagnosis of acute pancreatitis
was 0.96 (95% CI 0.78 to 0.99) and the summary estimate of
specificity for diagnosis of acute pancreatitis was 0.98 (95% CI
0.98 to 0.99). Excluding Chang 2011, for which there was major
concern about applicability, resulted in the inclusion of one study
(253 participants) in this analysis (Keim 1998). The estimate of
sensitivity for diagnosis of acute pancreatitis was 0.94 (95% CI
0.78 to 0.99) and the estimate of specificity for diagnosis of acute
pancreatitis was 0.95 (95% CI 0.91 to 0.97).
Two to three days after admission
One study (253 participants) was included in this analysis (Keim
1998). There was no incorporation bias in this study, as this study
used radiology as the reference standard.The estimate of sensitivity
for diagnosis of acute pancreatitis was 0.69 (95% CI 0.50 to 0.83)
and the estimate of specificity for diagnosis of acute pancreatitis
was 0.91 (95% CI 0.86 to 0.94).
Four to five days after admission
One study (253 participants) was included in this analysis (Keim
1998). There was no incorporation bias in this study, as this study
used radiology as the reference standard.The estimate of sensitivity
for diagnosis of acute pancreatitis was 0.41 (95% CI 0.24 to 0.59)
and the estimate of specificity for diagnosis of acute pancreatitis
was 0.84 (95% CI 0.79 to 0.89).
More than normal
On admission
A total of two studies (453 participants) were included in this
analysis (Keim 1998; Patt 1966). There was no incorporation bias
in either study, as Keim 1998 used radiology as the reference stan-
dard, while Patt 1966 used laparotomy or autopsy as the refer-
ence standard. Based on the -2 log likelihood ratio, random-effects
model for sensitivity and fixed-effect model for specificity were
used for meta-analysis. The summary estimate of sensitivity for
diagnosis of acute pancreatitis was 0.96 (95% CI 0.00 to 1.00)
and the summary estimate of specificity for diagnosis of acute pan-
creatitis was 0.83 (95% CI 0.47 to 0.96).
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Two to three days after admission
One study (253 participants) was included in this analysis (Keim
1998). There was no incorporation bias in this study, as this study
used radiology as the reference standard.The estimate of sensitivity
for diagnosis of acute pancreatitis was 0.97 (95% CI 0.82 to 1.00)
and the estimate of specificity for diagnosis of acute pancreatitis
was 0.79 (95% CI 0.73 to 0.84).
Four to five days after admission
One study (253 participants) was included in this analysis (Keim
1998). There was no incorporation bias in this study, as this study
used radiology as the reference standard.The estimate of sensitivity
for diagnosis of acute pancreatitis was 0.59 (95% CI 0.41 to 0.76)
and the estimate of specificity for diagnosis of acute pancreatitis
was 0.70 (95% CI 0.64 to 0.76).
Urinary trypsinogen-2
Actim Pancreatitis (Medix Biochemica) test (threshold: > 50
ng/mL)
A total of five studies (841 participants) were included in this
analysis (Abraham 2011; Aysan 2008; Mayumi 2012; Saez 2005;
Wu 2009). Of these, three studies used the consensus definition as
the reference standard (Abraham2011;Mayumi 2012; Saez 2005);
Aysan 2008 used radiology as the reference standard; andWu 2009
used pain, radiology, and amylase as the reference standard.
Based on the -2 log likelihood ratio, random-effects model for sen-
sitivity and fixed-effect model for specificity were used for meta-
analysis. The summary estimate of sensitivity for diagnosis of acute
pancreatitis was 0.72 (95% CI 0.56 to 0.84) and the summary
estimate of specificity for diagnosis of acute pancreatitis was 0.90
(95%CI 0.85 to 0.93).While four studies clearly stated the thresh-
old (Abraham 2011; Mayumi 2012; Saez 2005; Wu 2009), in one
study the threshold was unclear. Based on the authors’ description,
it appears the manufacturer’s threshold was used (Aysan 2008).
Consequently, we included this study in the primary analysis, but
performed a sensitivity analysis excluding this study. Based on the
-2 log likelihood ratio, random-effects model for sensitivity and
fixed-effect model for specificity were used for meta-analysis. The
summary estimate of sensitivity for diagnosis of acute pancreatitis
was 0.74 (95% CI 0.56 to 0.87) and the summary estimate of
specificity for diagnosis of acute pancreatitis was 0.89 (95% CI
0.84 to 0.93), that is there was only a minor change in summary
sensitivity and specificity by excluding this study.
Quantitative urinary trypsinogen (threshold: > 50 ng/mL)
One study (412 participants) was included in this analysis
(Mayumi 2012). The reference standard used in this study was
the consensus definition. The estimate of sensitivity for diagno-
sis of acute pancreatitis was 0.71 (95% CI 0.63 to 0.78) and the
estimate of specificity for diagnosis of acute pancreatitis was 0.89
(95% CI 0.84 to 0.92).
Urinary trypsinogen: only positive or most positive
(threshold not reported)
One study (412 participants) was included in this analysis
(Mayumi 2012). The reference standard used in this study was
the consensus definition. The estimate of sensitivity for diagno-
sis of acute pancreatitis was 0.60 (95% CI 0.51 to 0.67) and the
estimate of specificity for diagnosis of acute pancreatitis was 0.92
(95% CI 0.88 to 0.95).
Urinary amylase
Above normal (quantitative test)
One study (134 participants) was included in this analysis (Wu
2009). This study used pain, radiology, and amylase as the refer-
ence standard. The estimate of sensitivity for diagnosis of acute
pancreatitis was 0.83 (95% CI 0.65 to 0.94) and the estimate of
specificity for diagnosis of acute pancreatitis was 0.86 (95% CI
0.77 to 0.91).
One plus (qualitative test: 1+ (threshold level for 1+ not
stated))
One study (218 participants) was included in this analysis (Burkitt
1987). This study used pain and amylase greater than 1000 (nor-
mal = 300 IU) as the reference standard. The estimate of sensitivity
for diagnosis of acute pancreatitis was 0.66 (95% CI 0.49 to 0.79)
and the estimate of specificity for diagnosis of acute pancreatitis
was 0.94 (95% CI 0.90 to 0.97).
Two plus (qualitative test: 2+ (threshold level for 2+ not
stated))
One study (218 participants) was included in this analysis (Burkitt
1987). This study used pain and amylase greater than 1000 (nor-
mal = 300 IU) as the reference standard. The estimate of sensitivity
for diagnosis of acute pancreatitis was 0.44 (95% CI 0.29 to 0.60)
and the estimate of specificity for diagnosis of acute pancreatitis
was 0.99 (95% CI 0.96 to 1.00).
Comparison of different tests
Although we attempted to perform hierarchical summary receiver
operating characteristics curve (HSROC) analysis using test as a
covariate in order to compare the accuracy of the tests, the models
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did not converge. We were therefore unable to formally compare
the diagnostic performance of the different tests.
Investigation of heterogeneity
Because of sparse data, we did not investigate heterogeneity.
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Summary of findings
Population People with abdominal pain seen in emergency care
Setting Secondary care in various countries
Target con-
dition
Acute pancreat it is
Reference
standard
1. Consensus criteria.
2. Radiological features of acute pancreat it is.
3. Laparotomy or autopsy features of acute pancreat it is.
Pre-
test proba-
bility (preva-
lence of
acute pan-
creatitis)
22.6%
Index test Sensitivity Specificity Post-
test proba-
bility of a
positive test
1
Post- test
probability
of a negative
test1
Number of
false posi-
tives per 100
people hav-
ing a posi-
tive test
Number of
false nega-
tives per 100
people hav-
ing a nega-
tive test
Number of
studies
Number of
participants
Risk of bias Applicability
concerns
Inconsis-
tency
Serum amy-
lase (thresh-
old: > 3 t imes
normal) (on
admission)2
0.72 (95% CI
0.59 to 0.82)
0.93 (95% CI
0.66 to 0.99)
74.0% (95%
CI 33.4% to
94.1%)
8.1% (95% CI
5.4% to 12.
1%)
26 (95% CI 6
to 67)
8 (95% CI 5
to 12)
3 605 Unclear Low Moderate
Serum lipase
(threshold: >
3 t imes nor-
mal) (on ad-
0.79 (95% CI
0.54 to 0.92)
0.89 (95% CI
0.46 to 0.99)
68.1% (95%
CI 21.4% to
94.3%)
6.6% (95% CI
2.7% to 15.
1%)
32 (95% CI 6
to 79)
7 (95% CI 3
to 15)
4 678 Unclear Low Moderate
2
2
S
e
ru
m
a
m
y
la
se
a
n
d
lip
a
se
a
n
d
u
rin
a
r
y
try
p
sin
o
g
e
n
a
n
d
a
m
y
la
se
fo
r
d
ia
g
n
o
sis
o
f
a
c
u
te
p
a
n
c
re
a
titis
(R
e
v
ie
w
)
C
o
p
y
rig
h
t
©
2
0
1
7
T
h
e
C
o
c
h
ra
n
e
C
o
lla
b
o
ra
tio
n
.
P
u
b
lish
e
d
b
y
Jo
h
n
W
ile
y
&
S
o
n
s,
L
td
.
mission)2
Urinary
trypsinogen-
2 (threshold:
Act im Pan-
creat it is - all
studies; > 50
ng/ mL) (on
admission)
0.72 (95% CI
0.56 to 0.84)
0.90 (95% CI
0.85 to 0.93)
67.2% (95%
CI 57.3% to
75.7%)
8.4% (95% CI
5.2% to 13.
3%)
33 (95% CI
24 to 43)
8 (95% CI 5
to 13)
5 841 High Unclear Moderate
Urinary
trypsinogen-
2 (quant ita-
t ive) (thresh-
old: > 50 ng/
mL) (on ad-
mission)
0.71 (95% CI
0.63 to 0.78)
0.89 (95% CI
0.84 to 0.92)
65.6% (95%
CI 57.0% to
73.3%)
8.7% (95% CI
6.9% to 10.
9%)
34 (95% CI
27 to 43)
9 (95% CI 7
to 11)
1 412 High Low Not applica-
ble
Urinary
trypsinogen-
2 (threshold:
only + or
most posi-
t ive - the
threshold for
this was not
avail-
able) (on ad-
mission)
0.60 (95% CI
0.51 to 0.67)
0.92 (95% CI
0.88 to 0.95)
69.1% (95%
CI 59.0% to
77.6%)
11.4% (95%
CI 9.6% to
13.5%)
31 (95% CI
22 to 41)
11 (95% CI
10 to 13)
1 412 High Low Not applica-
ble
Urinary amy-
lase (quant i-
ta-
t ive) (thresh-
old: above
normal) (on
admission)
0.83 (95% CI
0.65 to 0.94)
0.86 (95% CI
0.77 to 0.91)
62.8% (95%
CI 50.8% to
73.5%)
5.4% (95% CI
2.5% to 11.
3%)
37 (95% CI
27 to 49)
5 (95% CI 2
to 11)
1 134 Unclear Unclear Not applica-
ble
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Urinary amy-
lase (qualita-
t ive) (thresh-
old: 1 plus)
(on admis-
sion)
0.66 (95% CI
0.49 to 0.79)
0.94 (95% CI
0.90 to 0.97)
77.3% (95%
CI 64.2% to
86.6%)
9.6% (95% CI
6.5% to 14.
0%)
23 (95% CI
13 to 36)
10 (95% CI 6
to 14)
1 218 High High Not applica-
ble
Urinary amy-
lase (qualita-
t ive) (thresh-
old: 2 plus)
(on admis-
sion)
0.44 (95% CI
0.29 to 0.60)
0.99 (95% CI
0.96 to 1.00)
95.8% (95%
CI 75.8% to
99.4%)
14.2% (95%
CI 11.2% to
17.8%)
4 (95% CI 1
to 24)
14 (95% CI
11 to 18)
1 218 High High Not applica-
ble
CI: conf idence interval
1The post-test probabilit ies were calculated at the median pre-test probability. At the lower quart ile of pre-test probability
of 16.3%, the post-test probabilit ies of posit ive test for serum amylase (more than three t imes normal), serum lipase (more
than three t imes normal), and urinary trypsinogen (more than 50 ng/ mL) were 65.5% (95% CI 25.1% to 91.5%); 58.7% (95%
CI 15.4% to 91.7%); and 57.7% (95% CI 47.2% to 67.5%), respect ively. At the same pre-test probability of 16.3%, the post-
test probabilit ies of negat ive test for serum amylase (more than three t imes normal), serum lipase (more than three t imes
normal), and urinary trypsinogen (more than 50 ng/ mL) were 5.6% (95% CI 3.7% to 8.4%); 4.5% (95% CI 1.8% to 10.6%); and
5.8% (95% CI 3.5% to 9.3%), respect ively. At the upper quart ile of pre-test probability of 47.3%, the post-test probabilit ies of
posit ive test for serum amylase (more than three t imes normal), serum lipase (more than three t imes normal), and urinary
trypsinogen (more than 50 ng/ mL) were 89.7% (95% CI 60.7% to 98.0%); 86.7% (95% CI 45.6% to 98.1%); and 86.3% (95% CI
80.5% to 90.6%), respect ively. At the same pre-test probability of 47.3%, the post-test probabilit ies of negat ive test for serum
amylase (more than three t imes normal), serum lipase (more than three t imes normal), and urinary trypsinogen (more than 50
ng/ mL) were 21.4% (95% CI 14.9% to 29.7%); 17.8% (95% CI 7.9% to 35.4%); and 22.0% (95% CI 14.4% to 32.0%), respect ively.
2The results do not include one study for which there was high concern about applicability.
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D I S C U S S I O N
Summary of main results
Ten studies including 5056 participants met the inclusion crite-
ria for this review and assessed the diagnostic accuracy of the in-
dex tests in people presenting to the emergency department with
acute abdominal pain (Abraham 2011; Aysan 2008; Burkitt 1987;
Chang 2011; Keim 1998; Mayumi 2012; Patt 1966; Saez 2005;
Viel 1990; Wu 2009). These 10 studies reported the diagnostic
test accuracy of the index tests at different thresholds. For the cur-
rently recommended threshold of above three times normal val-
ues, the summary sensitivities and specificities of admission serum
amylase and admission serum lipase were as follows.
• Serum amylase: sensitivity 0.71 (95% CI 0.65 to 0.77) and
specificity 0.99 (95% CI 0.99 to 0.99).
• Serum lipase: sensitivity 0.80 (95% CI 0.73 to 0.86) and
specificity 0.93 (95% CI 0.00 to 1.00).
However, one retrospective study excluded people with parotid
tumours and renal impairment; the inclusion of such patients will
decrease the diagnostic accuracy (Chang 2011). After excluding
this trial, which had high applicability concern in the participant
selection domain, the summary sensitivities and specificities of ad-
mission serum amylase and admission serum lipase were as fol-
lows.
• Serum amylase: sensitivity 0.72 (95% CI 0.59 to 0.82) and
specificity 0.93 (95% CI 0.66 to 0.99).
• Serum lipase: sensitivity 0.79 (95% CI 0.54 to 0.92) and
specificity 0.89 (95% CI 0.46 to 0.99).
In comparison, the admission urinary trypsinogen-2 was associ-
ated with a sensitivity of 0.72 (95% CI 0.56 to 0.84) and a speci-
ficity of 0.90 (95% CI 0.85 to 0.93). Thus, the tests appear to
have similar diagnostic test accuracy. While we could not perform
a formal comparison of the diagnostic test accuracy because of
sparse data, it is unlikely to demonstrate statistical significance
given the significant overlap of confidence intervals of sensitivities
(and specificities) in these three tests.
At the median prevalence of 22.6% of acute pancreatitis in the
studies, out of 100 people with positive test, serum amylase (more
than three times normal), serum lipase (more than three times nor-
mal), and urinary trypsinogen (more than 50 ng/mL), 74 (95%CI
33 to 94); 68 (95%CI 21 to 94); and 67 (95%CI 57 to 76) people
have acute pancreatitis, respectively; out of 100 people with neg-
ative test, serum amylase (more than three times normal), serum
lipase (more than three times normal), and urinary trypsinogen
(more than 50 ng/mL), 8 (95% CI 5 to 12); 7 (95% CI 3 to 15);
and 8 (95% CI 5 to 13) people have acute pancreatitis, respec-
tively. Thismeans that although negative index test result decreases
the probability of a person having acute pancreatitis, a significant
proportion of people with acute pancreatitis have negative results
and require further investigations to rule out acute pancreatitis,
depending upon the nature and intensity of their pain.
The diagnostic accuracy reported at other thresholds and times
was based on even less data and is subject to significant systematic
and random errors. The results presented should therefore be con-
sidered as exploratory information rather than information based
on which conclusions can be made. They indicate that a threshold
of twice the normal limit of both serum amylase and lipase should
be explored as an alternative to thrice the normal limit for the di-
agnosis of acute pancreatitis. The diagnostic accuracy also appears
to be less for both serum amylase and lipase as the time interval
between admission and the performance of the test increases, with
the diagnostic accuracy of serum amylase decreasing more than
serum lipase. Even the diagnostic accuracy of serum lipase in the
later days is not sufficiently accurate to have any clinical role. Un-
less future studies show a major improvement in diagnostic accu-
racy, it appears that these tests do not have major clinical roles,
that is a patient who has clinical symptoms of acute pancreati-
tis with a long time interval between the onset of symptoms and
performance of the test should undergo radiological tests directly
to confirm or rule out acute pancreatitis. One could also explore
urinary amylase as a potential triage test prior to radiological tests
for later days, as amylase gets excreted mainly by urine.
Strengths and weaknesses of the review
One of the main strengths of this review was that we searched the
literature thoroughly, without any publication or language restric-
tions. We did not use any diagnostic test accuracy filters in our
literature search because such filters could have led us to exclude
some relevant studies (Doust 2005). Inclusion of abstracts and
non-English articles may decrease the impact of publication bias
to a certain extent, although the determinants and the extent of
publication bias and selective reporting are not well known for di-
agnostic accuracy studies. We also planned to exclude case-control
studies because these studies are prone to bias (Whiting 2011).
Two review authors (KSG and OK, GR, or AH) independently
searched the references produced by the search to identify relevant
studies; screened the full-text papers against the inclusion criteria;
and extracted data. Data extractions by two review authors po-
tentially reduced the chance of errors related to data extraction by
a single review author (Buscemi 2006). Another strength of this
review was that we used the recommended methodological qual-
ity methods to assess the risk of bias and applicability concerns
in the included studies and took these into consideration while
interpreting the evidence.
Weaknesses
There were several shortcomings in our review. Firstly, the studies
included in the review had several methodological deficiencies.We
had to interpret the results of serum amylase and lipase without
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a study that included approximately two-thirds of the included
participants because of major concerns about applicability. An-
other major methodological deficiency was that three of the four
studies, Abraham 2011, Mayumi 2012, Saez 2005, and four of
the five studies, Abraham 2011, Mayumi 2012, Saez 2005, Wu
2009, that contributed to the assessment of diagnostic accuracy
of serum amylase and lipase used serum amylase and lipase as part
of the reference standard, which might have overestimated their
diagnostic test accuracy. Exclusion of these studies in a post hoc
sensitivity analysis left only a few studies at high risk of bias and
with applicability concerns to be included in the main analysis,
and increased the unreliability of the evidence. None of the stud-
ies reported whether the index tests and reference standards were
interpreted independently of one another. If they were not inter-
preted independently of each other, the accuracy of the tests would
have been overestimated. Only four studies reported that they in-
cluded all participants attending the emergency department with
acute abdominal pain (Abraham 2011; Mayumi 2012; Saez 2005;
Viel 1990). In three studies there was inappropriate exclusion of
participants (Burkitt 1987; Chang 2011; Patt 1966). Of particular
concern was the exclusion of people with parotid disease and end-
stage renal failure in one study (Chang 2011), which can overesti-
mate the diagnostic accuracy. Because of the large number of par-
ticipants included in this study, this study could have significantly
influenced the overall results and resulted in poor estimation of
diagnostic test accuracy. Future meta-analyses on this topic should
exclude Chang 2011 and other significantly biased studies that
use a very large number of participants because of the influence
of such studies on the result of the meta-analysis. It was unclear
whether inappropriate exclusions were avoided in the remaining
three studies (Aysan 2008; Keim 1998; Wu 2009). It was unclear
whether some of the participants had indeterminate values in any
of these six studies in which there were inappropriate exclusions
or those that did not report participant flow. Exclusion of people
with borderline values close to the threshold used or those with
other causes of elevation of these tests will overestimate the diag-
nostic test accuracy of these tests.
Secondly, there was significant heterogeneity in some of the com-
parisons. In the analysis of lipase more than three times normal on
admission with inclusion of Chang 2011, the confidence intervals
covered the entire range of possible specificities. While we could
have used the fixed-effect model to overcome these wide confi-
dence intervals, this would havemeant that wewould have ignored
heterogeneity that was evident in lack of overlap of confidence
intervals. This model would also have had a poorer fit than the
one we reported, leading us to make wrong conclusions as a result
of ignoring heterogeneity. The various reasons for heterogeneity
included different reference standards.
Thirdly, the sample sizes of the studies were small after the large
study was excluded due to major concerns about applicability in
the participant selection domain (Chang 2011), resulting in wide
confidence intervals. We found a large number of studies using
case-control study designs that compared the diagnostic perfor-
mance of the tests between people with acute pancreatitis and
healthy controls. While the inclusion of such studies would have
improved precision, it would have resulted in significant overes-
timation of the results. This would have been meaningless in the
context of how these tests are used in clinical practice, that is di-
agnose acute pancreatitis in people with acute abdominal pain.
We therefore accepted inclusion of fewer studies to provide a rea-
sonably reliable diagnostic test accuracy estimate. However, this
trade-off resulted in sparse data and prevented us from formally
comparing the different index tests and investigating heterogene-
ity. In particular, we were not able to assess whether the diagnostic
performance changes with a time interval between onset of clinical
symptoms and the performance of the test. As the half lifes of the
different tests are different, this is of great clinical significance.
Comparison with other reviews
In the systematic review by Chang 2012, the summary estimate
of urinary trypsinogen-2 was 0.82 (95% CI 0.79 to 0.85) and the
specificity was 0.94 (95% CI 0.92 to 0.95). These results show
greater diagnostic accuracy and a more precise estimate of the di-
agnostic accuracy compared to what we have found in this review.
The likely reason for this is the inclusion of studies with an inade-
quate reference standard, which would have resulted in improved
precision and may improve the diagnostic accuracy. The results
of the other systematic review by Jin 2013 were similar to those
of Chang 2012. Jin 2013 reported the diagnostic test accuracy
of serum amylase, serum lipase, and urinary trypsinogen-2, and
stated that the three tests had similar diagnostic test accuracies. We
agree with the inference that the diagnostic accuracies of serum
amylase, serum lipase, and urinary trypsinogen-2 are similar.
Applicability of findings to the review question
Generalisability of the results
The studies did not restrict the participants to specific aetiologies
of acute pancreatitis, therefore the findings of this review are ap-
plicable to all aetiologies of acute pancreatitis. Most studies used
the test in the same way that it is used in clinical practice, that
is in people with acute abdominal pain. Consequently, the results
are applicable in people with acute abdominal pain. None of the
studies reporting the diagnostic accuracy of tests post-endoscopic
retrograde cholangiopancreatography met the criteria for the ref-
erence standards used in this review, therefore the findings of this
review may not be applicable in patients undergoing endoscopic
retrograde cholangiopancreatography.
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Use of the test in the clinical setting
Themain role of the index test is diagnosis in clinical practice. Use
of a test with good diagnostic accuracy makes it possible to decide
on admission and appropriate management of patients with acute
abdominal pain. The post-test probabilities of positive and neg-
ative test depend upon the pre-test probabilities of the test. The
median pre-test probability observed in the trials included in this
review was 22.6%. Depending upon the type of people arriving at
the emergency department, this can vary; this pre-test probability
seems to be higher than that routinely seen in clinical practice.
This might be because the clinicians may have included only pa-
tients whom they suspect to have acute pancreatitis rather than any
patients with abdominal pain. At the median pre-test probability
of 22.6%, the post-test probabilities suggest that a significant pro-
portion of people with negative tests, that is an average of 7% to
9%, have pancreatitis. Even at the lower quartile of pre-test prob-
ability of 16.3%, an average of 5% to 6% of people with negative
tests have acute pancreatitis. People with severe abdominal pain
suggestive of acute pancreatitis may therefore require admission
for observation, pain control, and supportive treatment even if
one or more of the index tests is negative, as the implications of
missing acute pancreatitis in severe abdominal pain are high.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
About a quarter of people with acute pancreatitis fail to be diag-
nosed as having acute pancreatitis with the tests evaluated in this
review. Consequently, one should have a low threshold to admit
the patient and treat as acute pancreatitis if the symptoms are sug-
gestive of acute pancreatitis, even if these tests are normal. As about
1 in 10 patients without acute pancreatitis may be wrongly diag-
nosed as having acute pancreatitis with these tests, it is important
to consider other conditions that require urgent surgical interven-
tion such as perforated viscus even if these tests are abnormal.
The diagnostic performance of these tests decreases even further
with the progression of time, and one should have an even lower
threshold to perform additional investigations if the symptoms are
suggestive of acute pancreatitis.
Implications for research
Further well-designed diagnostic test accuracy studies with pre-
specified index test threshold of serum amylase, serum lipase, and
urinary trypsinogen-2 are required. Such studies should avoid in-
cluding the index test in the reference standard. Further well-de-
signed diagnostic test accuracy studies with prespecified index test
threshold of urinary amylase and urinary trypsinogen-2 are re-
quired to investigate the potential of these tests to diagnose acute
pancreatitis when there is a delay between onset of symptoms and
performance of the test.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Abraham 2011
Study characteristics Study characteristics
Patient sampling Type of study: prospective study.
Consecutive or random sample: consecutive patients.
Patient characteristics and set-
ting
Sample size: 124.
Females: not stated.
Median or median age: not stated.
Presentation:
Patients with acute abdominal pain.
Setting: secondary care, India.
Index tests Index test: serum amylase.
Further details:
Technical specifications: not stated.
Performed by: not stated.
Criteria for positive diagnosis: > 3 times normal.
Index test: serum lipase.
Further details:
Technical specifications: not stated.
Performed by: not stated.
Criteria for positive diagnosis: > 3 times normal.
Index test: urinary trypsinogen-2.
Further details:
Technical specifications: Actim Pancreatitis (Medix Biochemica).
Performed by: not stated.
Criteria for positive diagnosis: > 50 ng/mL.
Target condition and reference
standard(s)
Target condition: acute pancreatitis.
Reference standard: consensus definition.
Further details:
Technical specifications: not applicable.
Performed by: not stated.
Criteria for positive diagnosis: consensus definition.
For the index tests serum amylase and serum lipase, the answer for the signalling question ’Is the
reference standard independent of the index test?’ is ’No’ and the risk of bias is ’High risk’
Flow and timing Number of indeterminates for whom the results of reference standard were available: not stated.
Number of patients who were excluded from the analysis: not stated
Comparative
Notes The index tests serum amylase and lipase were not independent of the reference standard, but
urinary trypsinogen-2 was independent of the reference standard
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Abraham 2011 (Continued)
Methodological quality Methodological
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection DOMAIN 1: Patient
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Low Low
DOMAIN 2: Index Test Serum amylase DOMAIN 2: Index
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
If a threshold was used, was it
pre-specified?
Yes
Unclear Low
DOMAIN 2: Index Test Serum Lipase DOMAIN 2: Index
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
If a threshold was used, was it
pre-specified?
Yes
Unclear Low
DOMAIN 2: Index Test Urinary trypsinogen-2 (standard criteria) DOMAIN 2: Index
dard criteria)
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
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Abraham 2011 (Continued)
If a threshold was used, was it
pre-specified?
Yes
Unclear Low
DOMAIN 3: Reference Standard DOMAIN 3: Refer
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Is the reference standard inde-
pendent of the index test?
Yes
Unclear Low
DOMAIN 4: Flow and Timing DOMAIN 4: Flo
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
Did all patients receive a refer-
ence standard?
Yes
Unclear
Aysan 2008
Study characteristics Study characteristics
Patient sampling Type of study: prospective study.
Consecutive or random sample: unclear.
Patient characteristics and set-
ting
Sample size: 99.
Females: 46 (46.5%).
Median or median age: 37 years.
52Serum amylase and lipase and urinary trypsinogen and amylase for diagnosis of acute pancreatitis (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Aysan 2008 (Continued)
Presentation:
Patients with abdominal pain.
Exclusion criteria:
Patients with trauma or who required emergency surgical intervention.
Setting: secondary care, Turkey.
Index tests Index test: urinary trypsinogen-2.
Further details:
Technical specifications: Medix Biochemica.
Performed by: not stated.
Criteria for positive diagnosis: not clearly stated (probably used the manufacturer’s level of > 50 ng/
mL)
Target condition and reference
standard(s)
Target condition: acute pancreatitis.
Reference standard: CT scan.
Further details:
Technical specifications: not stated.
Performed by: radiologists.
Criteria for positive diagnosis: at least 1 of the following:
• increase in diameter of pancreas;
• irregular pancreas contours;
• peripancreatic fluid;
• peripancreatic gas accumulation.
Flow and timing Number of indeterminates for whom the results of reference standard were available: not stated.
Number of patients who were excluded from the analysis: not stated
Comparative
Notes
Methodological quality Methodological
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection DOMAIN 1: Patient
Was a consecutive or random
sample of patients enrolled?
Unclear
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Unclear
Unclear Unclear
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Aysan 2008 (Continued)
DOMAIN 2: Index Test Urinary trypsinogen-2 (standard criteria) DOMAIN 2: Index
dard criteria)
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
If a threshold was used, was it
pre-specified?
Yes
Unclear Unclear
DOMAIN 3: Reference Standard DOMAIN 3: Refer
Is the reference standards likely
to correctly classify the target
condition?
No
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Is the reference standard inde-
pendent of the index test?
Yes
High Low
DOMAIN 4: Flow and Timing DOMAIN 4: Flo
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Unclear
Did all patients receive a refer-
ence standard?
Yes
Unclear
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Burkitt 1987
Study characteristics Study characteristics
Patient sampling Type of study: prospective study.
Consecutive or random sample: neither.
Patient characteristics and set-
ting
Sample size: 306.
Females: not stated.
Median or median age: not stated.
Presentation:
People with abdominal pain.
Note: 88 patients who had normal urinary amylase were excluded from analysis.
Setting: seconday care, UK.
Index tests Index test: urinary amylase.
Further details:
Technical specifications: Rapignost-Amylase test.
Performed by: not stated.
Criteria for positive diagnosis: 1 plus.
Second criteria for positive diagnosis: 2 plus.
Target condition and reference
standard(s)
Target condition: acute pancreatitis.
Reference standard: Phadebas Amylase > 1000 (normal limit 300) + abdominal pain.
Further details:
Technical specifications: not stated.
Performed by: not stated.
Criteria for positive diagnosis: amylase > 1000 (normal limit 300) + abdominal pain
Flow and timing Number of indeterminates for whom the results of reference standard were available: not stated.
Number of patients who were excluded from the analysis: 88 (28.8%)
Comparative
Notes
Methodological quality Methodological
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection DOMAIN 1: Patient
Was a consecutive or random
sample of patients enrolled?
No
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Unclear
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Burkitt 1987 (Continued)
High High
DOMAIN 2: Index Test Urinary amylase DOMAIN 2: Index
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
If a threshold was used, was it
pre-specified?
Unclear
Unclear Low
DOMAIN 3: Reference Standard DOMAIN 3: Refer
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Is the reference standard inde-
pendent of the index test?
Yes
Unclear Low
DOMAIN 4: Flow and Timing DOMAIN 4: Flo
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Unclear
Did all patients receive a refer-
ence standard?
Yes
Unclear
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Chang 2011
Study characteristics Study characteristics
Patient sampling Type of study: retrospective study.
Consecutive or random sample: neither.
Patient characteristics and set-
ting
Sample size: 3451.
Females: not stated.
Median or median age: not stated.
Presentation:
Patients with acute abdominal pain and undergoing blood tests.
Exclusion criteria
Patients with parotid disease, intracranial haemorrhage, end-stage renal failure.
Setting: secondary care, Hong Kong, China.
Index tests Index test: serum amylase.
Further details:
Technical specifications: Beckman Coulter chemistry analyser.
Performed by: not stated.
Criteria for positive diagnosis: > 3 times normal.
Second criteria for positive diagnosis: > twice normal.
Index test: serum lipase.
Further details:
Technical specifications: Beckman Coulter chemistry analyser.
Performed by: not stated.
Criteria for positive diagnosis: > 3 times normal.
Second criteria for positive diagnosis: > twice normal.
Target condition and reference
standard(s)
Target condition: acute pancreatitis.
Reference standard: radiology (ultrasound or CT).
Further details:
Technical specifications: not stated.
Performed by: not stated.
Criteria for positive diagnosis: not stated.
Flow and timing Number of indeterminates for whom the results of reference standard were available: not stated.
Number of patients who were excluded from the analysis: not stated
Comparative
Notes
Methodological quality Methodological
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection DOMAIN 1: Patient
Was a consecutive or random
sample of patients enrolled?
No
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Chang 2011 (Continued)
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
No
High High
DOMAIN 2: Index Test Serum amylase DOMAIN 2: Index
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
If a threshold was used, was it
pre-specified?
Unclear
Unclear Low
DOMAIN 2: Index Test Serum Lipase DOMAIN 2: Index
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
If a threshold was used, was it
pre-specified?
Unclear
Unclear Low
DOMAIN 3: Reference Standard DOMAIN 3: Refer
Is the reference standards likely
to correctly classify the target
condition?
No
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Is the reference standard inde-
pendent of the index test?
Yes
High Low
DOMAIN 4: Flow and Timing DOMAIN 4: Flo
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Chang 2011 (Continued)
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Unclear
Did all patients receive a refer-
ence standard?
Yes
Unclear
Keim 1998
Study characteristics Study characteristics
Patient sampling Type of study: prospective study.
Consecutive or random sample: unclear.
Patient characteristics and set-
ting
Sample size: 253.
Females: 108 (42.7%).
Median or median age: 56 years.
Presentation:
Patients with acute abdominal pain and undergoing blood tests.
Setting: secondary care, Germany.
Index tests Index test: serum amylase.
Further details:
Technical specifications: Boehringer Mannheim.
Performed by: not stated.
Criteria for positive diagnosis: > twice normal.
Second criteria for positive diagnosis: > normal.
Index test: serum lipase.
Further details:
Technical specifications: Boehringer Mannheim.
Performed by: not stated.
Criteria for positive diagnosis: > twice normal.
Second criteria for positive diagnosis: > normal.
Serum amylase and lipase were measured at the 2 specified thresholds for each test at 3 different
time points (on admission, 2 to 3 days later, and 4 to 5 days later)
Target condition and reference
standard(s)
Target condition: acute pancreatitis.
Reference standard: radiology (ultrasound or CT).
Further details:
Technical specifications: not stated.
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Keim 1998 (Continued)
Performed by: not stated.
Criteria for positive diagnosis: not stated.
Flow and timing Number of indeterminates for whom the results of reference standard were available: not stated.
Number of patients who were excluded from the analysis: not stated
Comparative
Notes
Methodological quality Methodological
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection DOMAIN 1: Patient
Was a consecutive or random
sample of patients enrolled?
Unclear
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Unclear
Unclear Unclear
DOMAIN 2: Index Test Serum amylase DOMAIN 2: Index
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
If a threshold was used, was it
pre-specified?
No
High Low
DOMAIN 2: Index Test Serum Lipase DOMAIN 2: Index
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
If a threshold was used, was it
pre-specified?
No
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Keim 1998 (Continued)
High Low
DOMAIN 3: Reference Standard DOMAIN 3: Refer
Is the reference standards likely
to correctly classify the target
condition?
No
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Is the reference standard inde-
pendent of the index test?
Yes
High Low
DOMAIN 4: Flow and Timing DOMAIN 4: Flo
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Unclear
Did all patients receive a refer-
ence standard?
Yes
Unclear
Mayumi 2012
Study characteristics Study characteristics
Patient sampling Type of study: prospective study.
Consecutive or random sample: consecutive patients.
Patient characteristics and set-
ting
Sample size: 412.
Females: 186 (45.1%).
Median or median age: 55 years.
Presentation:
Adult patients with acute abdominal pain.
Setting: secondary care, Japan.
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Mayumi 2012 (Continued)
Index tests Index test: serum amylase.
Further details:
Technical specifications: BioMajesty JCA-BM or LABOSPECT.
Performed by: study collaborators.
Criteria for positive diagnosis: > 3 times normal.
Index test: serum lipase.
Further details:
Technical specifications: BioMajesty JCA-BM or LABOSPECT.
Performed by: study collaborators.
Criteria for positive diagnosis: > 3 times normal.
Index test: urinary trypsinogen-2.
Further details:
Technical specifications: Actim Pancreatitis (Medix Biochemica).
Performed by: study collaborators.
Criteria for positive diagnosis: > 50 ng/mL.
Second criteria for positive diagnosis: only + or most positive
Index test: urinary trypsinogen-2.
Further details:
Technical specifications: quantitative immunoenzymometric assay trypsinogen-2 test (Medix Bio-
chemica).
Performed by: study collaborators.
Criteria for positive diagnosis: > 50 ng/mL.
Target condition and reference
standard(s)
Target condition: acute pancreatitis.
Reference standard: consensus definition.
Further details:
Technical specifications: not stated.
Performed by: not stated.
Criteria for positive diagnosis: not stated.
Flow and timing Number of indeterminates for whom the results of reference standard were available: not stated.
Number of patients who were excluded from the analysis: not stated
Comparative
Notes The index tests serum amylase and lipase were not independent of the reference standard, but
urinary trypsinogen-2 was independent of the reference standard
Methodological quality Methodological
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection DOMAIN 1: Patient
Was a consecutive or random
sample of patients enrolled?
Yes
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Mayumi 2012 (Continued)
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Low Low
DOMAIN 2: Index Test Serum amylase DOMAIN 2: Index
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Low Low
DOMAIN 2: Index Test Serum Lipase DOMAIN 2: Index
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Low Low
DOMAIN 2: Index Test Urinary trypsinogen-2 (standard criteria) DOMAIN 2: Index
dard criteria)
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Low Low
DOMAIN 2: Index Test Urinary trypsinogen-2 (non-standard criteria) DOMAIN 2: Index
standard criteria)
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Mayumi 2012 (Continued)
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
No
High Low
DOMAIN 3: Reference Standard DOMAIN 3: Refer
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Is the reference standard inde-
pendent of the index test?
Yes
Unclear Low
DOMAIN 4: Flow and Timing DOMAIN 4: Flo
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Unclear
Did all patients receive a refer-
ence standard?
Yes
Unclear
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Patt 1966
Study characteristics Study characteristics
Patient sampling Type of study: unclear whether prospective or retrospective study.
Consecutive or random sample: neither.
Patient characteristics and set-
ting
Sample size: 200.
Females: not stated.
Median or median age: not stated.
Presentation:
• Patients with acute abdominal pain.
• Underwent laparotomy or autopsy.
Note: This indicates that only people with severe symptoms have been included.
Setting: secondary care, USA.
Index tests Index test: serum amylase.
Further details:
Technical specifications: not stated.
Performed by: not stated.
Criteria for positive diagnosis: > normal.
Index test: serum lipase.
Further details:
Technical specifications: calorimetric method.
Performed by: not stated.
Criteria for positive diagnosis: > normal.
Target condition and reference
standard(s)
Target condition: acute pancreatitis.
Reference standard: laparotomy or autopsy.
Further details:
Technical specifications: not stated.
Performed by: not stated.
Criteria for positive diagnosis: not stated.
Flow and timing Number of indeterminates for whom the results of reference standard were available: not stated.
Number of patients who were excluded from the analysis: not stated
Comparative
Notes
Methodological quality Methodological
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection DOMAIN 1: Patient
Was a consecutive or random
sample of patients enrolled?
No
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Patt 1966 (Continued)
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
No
High High
DOMAIN 2: Index Test Serum amylase DOMAIN 2: Index
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
If a threshold was used, was it
pre-specified?
Yes
Unclear Low
DOMAIN 2: Index Test Serum Lipase DOMAIN 2: Index
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
If a threshold was used, was it
pre-specified?
Yes
Unclear Low
DOMAIN 3: Reference Standard DOMAIN 3: Refer
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Is the reference standard inde-
pendent of the index test?
Yes
Unclear Low
DOMAIN 4: Flow and Timing DOMAIN 4: Flo
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Patt 1966 (Continued)
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Unclear
Did all patients receive a refer-
ence standard?
Yes
Unclear
Saez 2005
Study characteristics Study characteristics
Patient sampling Type of study: prospective study.
Consecutive or random sample: consecutive patients.
Patient characteristics and set-
ting
Sample size: 72.
Females: not stated.
Median or median age: not stated.
Presentation:
Patients with acute abdominal pain.
Setting: secondary care, Spain.
Index tests Index test: serum amylase.
Further details:
Technical specifications: Amyl, Boehringer Mannheim Systems.
Performed by: not stated.
Criteria for positive diagnosis: > 3 times normal.
Index test: serum lipase.
Further details:
Technical specifications: Lip, Boehringer Mannheim Systems.
Performed by: not stated.
Criteria for positive diagnosis: > 3 times normal.
Index test: urinary trypsinogen-2.
Further details:
Technical specifications: Actim Pancreatitis test strip.
Performed by: not stated.
Criteria for positive diagnosis: > 50 ng/mL.
Target condition and reference
standard(s)
Target condition: acute pancreatitis.
Reference standard: 3-fold increase of serum amylase and evidence of pancreatitis in radiology or
surgery.
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Saez 2005 (Continued)
Further details:
Technical specifications: not stated.
Performed by: not stated.
Criteria for positive diagnosis: not stated.
For the index test serum amylase, the answer for the signalling question ’Is the reference standard
independent of the index test?’ is ’No’ and the risk of bias is ’High risk’
Flow and timing Number of indeterminates for whom the results of reference standard were available: not stated.
Number of patients who were excluded from the analysis: not stated
Comparative
Notes The index test serum amylase was not independent of the reference standard, but serum lipase and
urinary trypsinogen-2 were independent of the reference standard
Methodological quality Methodological
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection DOMAIN 1: Patient
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Low Low
DOMAIN 2: Index Test Serum amylase DOMAIN 2: Index
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
If a threshold was used, was it
pre-specified?
Yes
Low Low
DOMAIN 2: Index Test Serum Lipase DOMAIN 2: Index
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
Unclear
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Saez 2005 (Continued)
dard?
If a threshold was used, was it
pre-specified?
Yes
Unclear Low
DOMAIN 2: Index Test Urinary trypsinogen-2 (standard criteria) DOMAIN 2: Index
dard criteria)
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
If a threshold was used, was it
pre-specified?
Yes
Low Low
DOMAIN 3: Reference Standard DOMAIN 3: Refer
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Is the reference standard inde-
pendent of the index test?
Yes
Unclear Low
DOMAIN 4: Flow and Timing DOMAIN 4: Flo
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
Did all patients receive a refer-
ence standard?
Yes
69Serum amylase and lipase and urinary trypsinogen and amylase for diagnosis of acute pancreatitis (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Saez 2005 (Continued)
Unclear
Viel 1990
Study characteristics Study characteristics
Patient sampling Type of study: unclear whether prospective or retrospective study.
Consecutive or random sample: consecutive patients.
Patient characteristics and set-
ting
Sample size: 83.
Females: not stated.
Median or median age: not stated.
Presentation:
Patients with acute abdominal pain.
Setting: secondary care, France.
Index tests Index test: serum lipase.
Further details:
Technical specifications: Boehringer Mannheim.
Performed by: not stated.
Criteria for positive diagnosis: > 3 times normal.
Target condition and reference
standard(s)
Target condition: acute pancreatitis.
Reference standard: 3-fold increase of serum amylase and evidence of pancreatitis in radiology,
endoscopic retrograde cholangiopancreatography, or surgery.
Further details:
Technical specifications: not stated.
Performed by: not stated.
Criteria for positive diagnosis: not stated.
Flow and timing Number of indeterminates for whom the results of reference standard were available: not stated.
Number of patients who were excluded from the analysis: not stated
Comparative
Notes
Methodological quality Methodological
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection DOMAIN 1: Patient
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
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Viel 1990 (Continued)
Did the study avoid inappropri-
ate exclusions?
Yes
Low Low
DOMAIN 2: Index Test Serum Lipase DOMAIN 2: Index
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
If a threshold was used, was it
pre-specified?
Yes
Unclear Low
DOMAIN 3: Reference Standard DOMAIN 3: Refer
Is the reference standards likely
to correctly classify the target
condition?
No
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Is the reference standard inde-
pendent of the index test?
Yes
High Low
DOMAIN 4: Flow and Timing DOMAIN 4: Flo
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
Did all patients receive a refer-
ence standard?
Yes
Unclear
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Wu 2009
Study characteristics Study characteristics
Patient sampling Type of study: unclear whether prospective or retrospective study.
Consecutive or random sample: unclear.
Patient characteristics and set-
ting
Sample size: 134.
Females: 66 (49.3%).
Median or median age: 48 years.
Presentation:
Patients with acute abdominal pain.
Setting: secondary care, China.
Index tests Index test: serum amylase.
Further details:
Technical specifications: Beckman automatic biochemical analyzer.
Performed by: not stated.
Criteria for positive diagnosis: > normal.
Target condition and reference
standard(s)
Target condition: acute pancreatitis.
Reference standard:
1. Characteristic pain.
2. Radiology.
3. Raised amylase.
Further details:
Technical specifications: not stated.
Performed by: not stated.
Criteria for positive diagnosis: not stated.
Flow and timing Number of indeterminates for whom the results of reference standard were available: not stated.
Number of patients who were excluded from the analysis: not stated
Comparative
Notes The index test serum amylase was not independent of the reference standard, but serum lipase and
urinary amylase were independent of the reference standard
Methodological quality Methodological
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection DOMAIN 1: Patient
Was a consecutive or random
sample of patients enrolled?
Unclear
Was a case-control design
avoided?
Yes
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Wu 2009 (Continued)
Did the study avoid inappropri-
ate exclusions?
Unclear
Unclear Unclear
DOMAIN 2: Index Test Serum amylase DOMAIN 2: Index
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
If a threshold was used, was it
pre-specified?
Yes
Unclear Low
DOMAIN 2: Index Test Urinary trypsinogen-2 (standard criteria) DOMAIN 2: Index
dard criteria)
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
If a threshold was used, was it
pre-specified?
Yes
Unclear Low
DOMAIN 2: Index Test Urinary amylase DOMAIN 2: Index
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
If a threshold was used, was it
pre-specified?
Yes
Unclear Low
DOMAIN 3: Reference Standard DOMAIN 3: Refer
Is the reference standards likely
to correctly classify the target
condition?
No
73Serum amylase and lipase and urinary trypsinogen and amylase for diagnosis of acute pancreatitis (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Wu 2009 (Continued)
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Is the reference standard inde-
pendent of the index test?
Yes
High Low
DOMAIN 4: Flow and Timing DOMAIN 4: Flo
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Unclear
Did all patients receive a refer-
ence standard?
Yes
Unclear
CT: computed tomography
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Abascal 1982 No diagnostic test accuracy data
Abate 1979 Inappropriate population
Acero 1982 Case-control study
Adam 1986 No diagnostic test accuracy data
Adams 1968 No diagnostic test accuracy data
Adler 1985 Inappropriate reference standard
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(Continued)
Ahmed 2009 Inappropriate population
Aho 1988 No diagnostic test accuracy data
Aho 1989 No diagnostic test accuracy data
Alvarez 1998 Not a primary research study
Anand 1956 Inappropriate population
Andersen 2010 Case-control study
Andre 1967 Inappropriate population
Andren-Sandberg 1997 Not a primary research study
Andriushchenko 1998 Inappropriate population
Anonymous 1966 Not a primary research study
Anonymous 2012 Not a primary research study
Aparisi 1987 Not a primary research study
Apple 1991 Inappropriate reference standard
Arzoglou 1983 Inappropriate population
Arzoglou 1986 Case-control study
Bacchini 1980 Inappropriate population
Bachmann 1979 Case-control study
Baillie 1997 Not a primary research study
Baillie 1998 Not a primary research study
Bang 2016 Inappropriate population
Banks 1996 Inappropriate population
Barbado 1977 Case-control study
Barbieri 2016 Not a primary research study
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Bargum 1983 No diagnostic test accuracy data
Barnett 1986 Inappropriate population
Batra 2015 Inappropriate population
Batsakis 1965 Not a primary research study
Benini 1987 Inappropriate reference standard
Benini 1987a Inappropriate population
Benini 1992 Inappropriate reference standard
Berger 1976 Case-control study
Bernard 1959 No diagnostic test accuracy data
Bernard 1964 Not a primary research study
Bernard 1964a Not a primary research study
Bernard 1964b Not a primary research study
Berry 1982 Inappropriate population
Blamey 1983 Inappropriate population
Bluskina 1966 Case-control study
Bode 1987 Not a primary research study
Borda 1978 Case-control study
Borgstrom 1984 Inappropriate population
Borgstrom 2002 Not a primary research study
Bowen 1983 Inappropriate population
Brailski 1975 Not a primary research study
Branford 1948 No diagnostic test accuracy data
Brault 1985 Inappropriate population
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Brisinda 1999 Inappropriate population
Brkic 1966 Not a primary research study
Brodie 1977 Inappropriate population
Brohee 1980 Inappropriate population
Brohee 1981 Not a primary research study
Brohee 1987 Not a primary research study
Brunner 1980 Not a primary research study
Buchler 1986 Inappropriate population
Budd 1959 Inappropriate population
Bunodiere 1975 Inappropriate population
Butler 2000 Not a primary research study
Caillens 1980 Inappropriate target condition
Calkins 1968 Inappropriate population
Cameron 1973 Inappropriate population
Campbell 1979 Inappropriate population
Caputo 1983 Inappropriate population
Cases 1988 Inappropriate population
Cevik 2010 Case-control study
Chase 1996 Inappropriate reference standard
Chen 1994 Case-control study
Chen 2004 Not a primary research study
Chen 2005 Inappropriate reference standard
Cheng 2004 Inappropriate population
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Cheung 2015 No diagnostic test accuracy data
Choi 2009 Case-control study
Choudhary 2012 Not a primary research study
Christoforidis 2002 Inappropriate population
Chylinski 1972 Inappropriate population
Chylinski 1978 Inappropriate population
Cintra 1952 Inappropriate population
Cintra 1953 Inappropriate population
Clave 1995 Inappropriate reference standard
Close 1987 Not a primary research study
Coffey 2014 Inappropriate population
Coffey 2014a Inappropriate population
Collins 1982 Case-control study
Concepcion Martin 2013 Inappropriate population
Concepcion-Martin 2016 No diagnostic test accuracy data
Corfield 1984 Inappropriate population
Cornett 2010 No diagnostic test accuracy data
Corsetti 1993 Inappropriate reference standard
Cote 1979 Inappropriate population
Courtois 1986 Inappropriate population
Dalgat 1986 Inappropriate population
Dankner 1951 Inappropriate population
Dati 1988 Not a primary research study
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de Boer 1986 Not a primary research study
De Leo 1954 Not a primary research study
Dehesa 1979 Case-control study
Delcourt 1977 Not a primary research study
Deril 1989 Case-control study
Deril 1992 Not a primary research study
Devanath 2009 Inappropriate population
Diaz 2009 Inappropriate population
Distefano 1952 No diagnostic test accuracy data
Domenech 1999 No diagnostic test accuracy data
Donaldson 1977 No diagnostic test accuracy data
Dreiling 1974 Inappropriate population
Dreiung 1954 Inappropriate population
Dronov 2009 Inappropriate population
Drozdov 2003 Not a primary research study
Durr 1977 Inappropriate population
Durr 1983 No diagnostic test accuracy data
Eckfeldt 1985 No diagnostic test accuracy data
Elman 1942 Not a primary research study
Engel 1977 No diagnostic test accuracy data
Ermini 1964 Not a primary research study
Esber 1995 Inappropriate population
Esperov 1972 Inappropriate population
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Fabris 1976 No diagnostic test accuracy data
Farkas 1967 No diagnostic test accuracy data
Farrar 1978 Inappropriate population
Finke 1978 Inappropriate population
Fiocca 1983 Inappropriate population
Fiorucci 1986 Inappropriate population
Fishman 1955 Inappropriate population
Flamion 1987 Inappropriate population
Forell 1959 Inappropriate population
Forest 1990 Inappropriate reference standard
Fridhandler 1972 Inappropriate population
Frost 1978 Inappropriate population
Fruchart 1974 Inappropriate population
Fruchart 1980 Inappropriate population
Fujiki 1980 Inappropriate population
Fujita 1989 Inappropriate population
Fukumoto 1981 Inappropriate population
Gambill 1975 Not a primary research study
Garden 1985 No diagnostic test accuracy data
Gilbert 1955 No diagnostic test accuracy data
Gluskina 1965 Inappropriate population
Gomez 2012 Inappropriate population
Gonzalez 1978 Case-control study
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Grinblatt 1997 Not a primary research study
Grosberg 1979 Case-control study
Gullo 2005 Not a primary research study
Gumaste 1991 Inappropriate population
Gumaste 1992 Case-control study
Gumaste 1993 Case-control study
Gumaste 1993a Not a primary research study
Gungor 2011 Inappropriate population
Gunn 1986 Inappropriate population
Guth 1960 Inappropriate population
Gwozdz 1990 Inappropriate reference standard
Haas 1985 Inappropriate population
Haffter 1981 Case-control study
Haffter 1983 Case-control study
Hale 2015 Inappropriate population
Hathaway 1983 Case-control study
Hayakawa 1985 Case-control study
Hayakawa 1989 Case-control study
Hedstroem 1998 Inappropriate reference standard
Hedstrom 1994 Case-control study
Hedstrom 1996 Case-control study
Hedstrom 1996a Case-control study
Hedstrom 1996b Case-control study
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Hedstrom 1996c Case-control study
Hedstrom 2001 Case-control study
Heer 1983 Case-control study
Hegewald 1998 Inappropriate population
Hegewald 1999 Inappropriate population
Hegewald 2001 Inappropriate population
Hemingway 1988 Case-control study
Hendry 1987 Inappropriate population
Henry 1957 Inappropriate population
Hoferichter 1964 Inappropriate population
Hoffman 1991 Inappropriate reference standard
Hofmeyr 2014 Inappropriate population
Holdsworth 1984 Case-control study
Holmes 2011 Inappropriate population
Horanyi 1984 Inappropriate population
Hostein 1976 Inappropriate population
Hostein 1977 Inappropriate population
Hostein 1978 Inappropriate population
Houry 1985 Inappropriate reference standard
Houry 1989 Inappropriate reference standard
Huang 2010 Inappropriate population
Huguet 1993 Inappropriate reference standard
Husain 2004 Inappropriate population
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Hwang 2004 Case-control study
Ignjatovic 1997 Inappropriate reference standard
Ignjatovic 2000 Inappropriate reference standard
Im 2010 Inappropriate population
Imrie 1979 Inappropriate population
Ito 2007 Inappropriate population
Jacobson 1982 Not a primary research study
Jam 1978 Inappropriate population
Jang 2007 Inappropriate population
Jensen 1970 Inappropriate population
Jin 2012 Not a primary research study
Jin 2013 Not a primary research study
Jin 2013a Not a primary research study
Johnson 2004 Inappropriate population
Jordanov 2009 Case-control study
Joshi 2008 Inappropriate reference standard
Junge 1982 Case-control study
Kaiser 1987 Inappropriate reference standard
Kamer 2007 Case-control study
Kameya 1985 Case-control study
Kameya 1986 Case-control study
Kapetanos 2007 Inappropriate population
Karlsson 1979 Inappropriate population
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Kaw 2001 Inappropriate population
Kazmierczak 1991 Inappropriate reference standard
Kehl 1985 Inappropriate population
Keim 2003 Case-control study
Kemppainen 1997 Inappropriate reference standard
Kemppainen 1997a Inappropriate population
Kemppainen 1997b Inappropriate population
Kemppainen 1997c Inappropriate reference standard
Kemppainen 1997d Not a primary research study
Kerlin 1986 Inappropriate population
Khrapach 1992 Inappropriate population
Khvatova 1973 Inappropriate population
Kim 2015 Inappropriate population
King 1995 Inappropriate population
Kirchner 1976 Inappropriate population
Kitterer 2015 Inappropriate population
Kobayashi 2011 Inappropriate population
Koehler 1982 Inappropriate population
Kolars 1982 Inappropriate population
Kolars 1984 Inappropriate population
Kopacova 2010 Inappropriate population
Kubo 1975 Not a primary research study
Kulikovsky 2014 Inappropriate population
84Serum amylase and lipase and urinary trypsinogen and amylase for diagnosis of acute pancreatitis (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(Continued)
Kurti 2011 Inappropriate reference standard
Kusama 1956 Inappropriate population
Kutter 1983 Inappropriate population
Kylanpaa-Back 1999 Inappropriate reference standard
Kylanpaa-Back 2000 Inappropriate reference standard
Kylanpaa-Back 2000a Inappropriate reference standard
Kylanpaa-Back 2002 Inappropriate reference standard
Lacher 1986 Inappropriate population
Lankisch 1977 Case-control study
Lankisch 1977a Case-control study
Lankisch 1994 Inappropriate population
Lankisch 1994a Inappropriate population
Lankisch 2006 Inappropriate population
Lankisch 2012 No diagnostic test accuracy data
Laurent-Puig 1992 Inappropriate population
Lauschke 1963 Inappropriate population
Leclerc 1983 Inappropriate population
Lee 1995 Case-control study
Lee 1996 Not a primary research study
Lempinen 2001 Inappropriate population
Lempinen 2003 Inappropriate population
Lessinger 1994 Case-control study
Levitt 1975 Not a primary research study
85Serum amylase and lipase and urinary trypsinogen and amylase for diagnosis of acute pancreatitis (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(Continued)
Lifton 1974 Inappropriate population
Lifton 1974a Inappropriate population
Ligny 1987 Case-control study
Lin 1989 Case-control study
Lindahl 1979 No diagnostic test accuracy data
Liyanage 2012 Inappropriate population
Logrono 2000 Inappropriate reference standard
Long 1976 Case-control study
Loo 1992 Not a primary research study
Lott 1985 Not a primary research study
Lott 1985a Not a primary research study
Lott 1986 Inappropriate population
Lott 1991 Not a primary research study
Lott 1991a Case-control study
Luengo 1996 Inappropriate population
Lunghi 1984 Inappropriate population
MacArthur 2013 Inappropriate population
Macgregor 1976 Case-control study
Maekelae 1997 Inappropriate population
Majkicsingh 1986 Inappropriate population
Malfertheiner 1989 Inappropriate population
Mangano 1990 Inappropriate target condition
Marten 1976 Case-control study
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Masoero 1978 Inappropriate population
Masoero 1980 Case-control study
Massey 1985 Inappropriate reference standard
Mayer 1985 Inappropriate reference standard
McCulloch 1984 Case-control study
McIntosh 1976 Not a primary research study
McMahon 1981 Inappropriate population
McMahon 1982 Inappropriate population
Merina 1957 Inappropriate population
Millat 1999 Not a primary research study
Miller 1973 Inappropriate population
Millson 1998 Inappropriate reference standard
Mimoz 1993 Inappropriate population
Mingxin 2001 Inappropriate reference standard
Mirmiranyazdy 1995 Inappropriate population
Mohamed 1989 Case-control study
Moller-Petersen 1983 Inappropriate reference standard
Moller-Petersen 1985 Inappropriate reference standard
Moller-Petersen 1986 Inappropriate reference standard
Morel 1981 Case-control study
Murray 1976 Inappropriate reference standard
Murray 1977 Inappropriate reference standard
Murray 1980 Inappropriate reference standard
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(Continued)
Navarro 1984 Not a primary research study
Navarro 1987 Case-control study
Nechai 1973 Inappropriate population
Nechiporuk 1982 Inappropriate population
Neoptolemos 1990 No diagnostic test accuracy data
Neoptolemos 1993 Not a primary research study
Neoptolemos 2000 Inappropriate population
Neovius 1984 Inappropriate reference standard
Neves 1985 Inappropriate population
Newland 2002 Inappropriate population
Oellerich 1983 Case-control study
Orda 1982 Inappropriate reference standard
Orda 1984 Case-control study
Orebaugh 1994 Inappropriate population
Osipov 1970 Inappropriate population
Ostrovskii 2012 Inappropriate population
Otsuki 1995 Case-control study
Pace 1985 Inappropriate population
Pacheco 2003 Case-control study
Pakkala 2012 Inappropriate population
Panteghini 1989 Inappropriate population
Panteghini 1990 Inappropriate population
Panteghini 1992 Inappropriate population
88Serum amylase and lipase and urinary trypsinogen and amylase for diagnosis of acute pancreatitis (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(Continued)
Papaioannou 1996 Case-control study
Papp 1969 Case-control study
Parodi 1983 Case-control study
Pereiaslov 1999 Inappropriate population
Peromingo 2009 Inappropriate population
Pezzilli 1992 Case-control study
Pezzilli 1992a Case-control study
Pezzilli 1994 Case-control study
Pezzilli 1997 Inappropriate population
Pezzilli 1998 Case-control study
Pezzilli 1999 Case-control study
Pezzilli 1999a Case-control study
Pezzilli 2000 Case-control study
Pezzilli 2001 Inappropriate population
Pezzilli 2004 Case-control study
Phillip 2013 Inappropriate population
Pirolla 2015 Inappropriate population
Ponseti-Bosch 1977 Case-control study
Ponteziere 2001 Inappropriate reference standard
Popivanov 1963 No diagnostic test accuracy data
Protsenko 1966 No diagnostic test accuracy data
Raju 2003 Case-control study
Raty 2007 Inappropriate population
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(Continued)
Reilly 2011 Inappropriate population
Rick 1968 Inappropriate population
Roberts 1985 Case-control study
Roberts 1987 Case-control study
Rodriguez-Cuartero 2000 No diagnostic test accuracy data
Rokicki 1976 Not a primary research study
Rosenblum 1991 Not a primary research study
Rosenburg 1957 No diagnostic test accuracy data
Rudis 2014 Inappropriate population
Ruzena 1989 No diagnostic test accuracy data
Sacchetti 1988 Inappropriate population
Sacchetti 1989 Inappropriate population
Sadowski 1992 Inappropriate population
Sainio 1995 Case-control study
Sankaralingam 2007 Inappropriate population
Satz 1989 Case-control study
Satz 1990 Case-control study
Satz 1990a Case-control study
Saxon 1957 Case-control study
Schmidt 2004 Inappropriate population
Scholz 1979 No diagnostic test accuracy data
Schultis 1969 No diagnostic test accuracy data
Schultis 1969a Inappropriate reference standard
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(Continued)
Schultis 1973 Case-control study
Schwokowski 1979 Not a primary research study
Scottolini 1977 Not a primary research study
Serra 2011 Inappropriate population
Siede 1969 Not a primary research study
Singh 2002 Inappropriate population
Singh 2004 Inappropriate population
Smith 2005 Inappropriate population
Solomon 1978 Not a primary research study
Steinberg 1983 Inappropriate reference standard
Steinberg 1985 Case-control study
Sternby 1996 Inappropriate population
Strebel 1970 Inappropriate population
Su 2010 Inappropriate reference standard
Suehiro 1984 Case-control study
Sutton 2009 Inappropriate population
Szalaj 1973 Case-control study
Testoni 1999 Inappropriate population
Testoni 1999a Inappropriate population
Testoni 2001 Inappropriate population
Thomson 1987 Inappropriate reference standard
Ticktin 1965 Inappropriate population
Tietz 1986 Inappropriate population
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(Continued)
Tomaszewski 1984 Inappropriate population
Torrens 1998 No diagnostic test accuracy data
Tournut 1978 Inappropriate population
Treacy 2001 Inappropriate population
Tsai 1988 Inappropriate population
Tseng 2011 Inappropriate population
Tvorogova 1991 Not a primary research study
Uhl 1992 Case-control study
Uminska 1985 Case-control study
Van Hee 1979 Case-control study
Van Ingen 1992 Case-control study
Varas 1994 Inappropriate population
Vega 1981 Inappropriate reference standard
Ventrucci 1983 Case-control study
Ventrucci 1985 Inappropriate reference standard
Ventrucci 1986 Case-control study
Ventrucci 1989 Case-control study
Ventrucci 1992 Case-control study
Ventrucci 1994 Case-control study
Wajda 1978 Inappropriate population
Walker 2013 Inappropriate population
Waller 1971 Inappropriate population
Wang 2009 Inappropriate population
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(Continued)
Warshaw 1975 Case-control study
Weaver 1985 Inappropriate population
Werner 1989 Case-control study
Wilson 2005 Case-control study
Winslet 1990 Inappropriate population
Wyatt 1974 No diagnostic test accuracy data
Wyllie 1979 Inappropriate population
Xu 2008 Case-control study
Xu 2010 Inappropriate reference standard
Yang 1987 Case-control study
Yang 2005 Case-control study
Zakrzewska 1982 Case-control study
Zakrzewska 1985 Case-control study
Zaninotto 1990 Case-control study
Zastrow 1973 Inappropriate population
Zeng 2010 Not a primary research study
Zeze 1975 Case-control study
Zhang 2010 Case-control study
Zharkovskaia 1978 Inappropriate population
Zheltvai 1969 Not a primary research study
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Characteristics of studies awaiting classification [ordered by study ID]
Anand 1956a
Study characteristics Study characteristics
Patient sampling Awaiting full text
Patient characteristics and set-
ting
Index tests
Target condition and reference
standard(s)
Flow and timing
Comparative
Notes
Cherry 1953
Study characteristics Study characteristics
Patient sampling Awaiting full text
Patient characteristics and set-
ting
Index tests
Target condition and reference
standard(s)
Flow and timing
Comparative
Notes
Coppola 1954
Study characteristics Study characteristics
Patient sampling Awaiting full text
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Coppola 1954 (Continued)
Patient characteristics and set-
ting
Index tests
Target condition and reference
standard(s)
Flow and timing
Comparative
Notes
Do Prado 1952
Study characteristics Study characteristics
Patient sampling Awaiting full text
Patient characteristics and set-
ting
Index tests
Target condition and reference
standard(s)
Flow and timing
Comparative
Notes
Lippi 2013
Study characteristics Study characteristics
Patient sampling Awaiting full text
Patient characteristics and set-
ting
Index tests
Target condition and reference
standard(s)
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Lippi 2013 (Continued)
Flow and timing
Comparative
Notes
Stimac 1995
Study characteristics Study characteristics
Patient sampling Awaiting full text
Patient characteristics and set-
ting
Index tests
Target condition and reference
standard(s)
Flow and timing
Comparative
Notes
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D A T A
Presented below are all the data for all of the tests entered into the review.
Tests. Data tables by test
Test
No. of
studies
No. of
participants
1 Serum amylase > 3 times normal 4 4056
2 Serum amylase > 3 times normal
(sensitivity analysis excluding
studies with incorporation bias)
1 3451
3 Serum amylase > 3 times normal
(sensitivity analysis excluding
Chang 2011)
3 605
4 Serum amylase > twice normal 2 3704
5 Serum amylase > twice normal
(sensitivity analysis excluding
Chang 2011)
1 253
6 Serum amylase > twice normal
(2 to 3 days)
1 253
7 Serum amylase > twice normal
(4 to 5 days)
1 253
8 Serum amylase > normal 3 587
9 Serum amylase > normal
(sensitivity analysis excluding
studies with incorporation bias)
2 453
10 Serum amylase > normal (2 to
3 days)
1 253
11 Serum amylase > normal (4 to
5 days)
1 253
12 Serum lipase > 3 times normal 5 4129
13 Serum lipase > 3 times normal
(sensitivity analysis excluding
studies with incorporation bias)
2 3534
14 Serum lipase > 3 times normal
(sensitivity analysis excluding
Chang 2011)
4 678
15 Serum lipase > twice normal 2 3704
16 Serum lipase > twice normal
(sensitivity analysis excluding
Chang 2011)
1 253
17 Serum lipase > twice normal (2
to 3 days)
1 253
18 Serum lipase > twice normal (4
to 5 days)
1 253
19 Serum lipase > normal 2 453
20 Serum lipase > normal (2 to 3
days)
1 253
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21 Serum lipase > normal (4 to 5
days)
1 253
22 Urinary trypsinogen-2 > 50
ng/mL (Actim Pancreatitis)
5 841
23 Urinary trypsinogen-2 > 50
ng/mL (Actim Pancreatitis -
sensitivity analysis)
4 742
24 Urinary trypsinogen-2 > 50
ng/mL (quantitative method)
1 412
25 Urinary trypsinogen-2 only
positive or most positive
(threshold for this not available)
1 412
26 Urinary amylase > normal
(quantitative)
1 134
27 Urinary amylase 1+ (qualitative) 1 218
28 Urinary amylase 2+ (qualitative) 1 218
Test 1. Serum amylase > 3 times normal.
Review: Serum amylase and lipase and urinary trypsinogen and amylase for diagnosis of acute pancreatitis
Test: 1 Serum amylase > 3 times normal
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Abraham 2011 52 7 17 48 0.75 [ 0.64, 0.85 ] 0.87 [ 0.76, 0.95 ]
Chang 2011 14 19 8 3410 0.64 [ 0.41, 0.83 ] 0.99 [ 0.99, 1.00 ]
Mayumi 2012 109 9 47 244 0.70 [ 0.62, 0.77 ] 0.96 [ 0.93, 0.98 ]
Saez 2005 37 3 13 19 0.74 [ 0.60, 0.85 ] 0.86 [ 0.65, 0.97 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 2. Serum amylase > 3 times normal (sensitivity analysis excluding studies with incorporation bias).
Review: Serum amylase and lipase and urinary trypsinogen and amylase for diagnosis of acute pancreatitis
Test: 2 Serum amylase > 3 times normal (sensitivity analysis excluding studies with incorporation bias)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Chang 2011 14 19 8 3410 0.64 [ 0.41, 0.83 ] 0.99 [ 0.99, 1.00 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 3. Serum amylase > 3 times normal (sensitivity analysis excluding Chang 2011).
Review: Serum amylase and lipase and urinary trypsinogen and amylase for diagnosis of acute pancreatitis
Test: 3 Serum amylase > 3 times normal (sensitivity analysis excluding Chang 2011)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Abraham 2011 52 7 17 48 0.75 [ 0.64, 0.85 ] 0.87 [ 0.76, 0.95 ]
Mayumi 2012 109 9 47 244 0.70 [ 0.62, 0.77 ] 0.96 [ 0.93, 0.98 ]
Saez 2005 37 3 13 19 0.74 [ 0.60, 0.85 ] 0.86 [ 0.65, 0.97 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 4. Serum amylase > twice normal.
Review: Serum amylase and lipase and urinary trypsinogen and amylase for diagnosis of acute pancreatitis
Test: 4 Serum amylase > twice normal
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Chang 2011 18 36 4 3393 0.82 [ 0.60, 0.95 ] 0.99 [ 0.99, 0.99 ]
Keim 1998 23 4 9 217 0.72 [ 0.53, 0.86 ] 0.98 [ 0.95, 1.00 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 5. Serum amylase > twice normal (sensitivity analysis excluding Chang 2011).
Review: Serum amylase and lipase and urinary trypsinogen and amylase for diagnosis of acute pancreatitis
Test: 5 Serum amylase > twice normal (sensitivity analysis excluding Chang 2011)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Keim 1998 23 4 9 217 0.72 [ 0.53, 0.86 ] 0.98 [ 0.95, 1.00 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 6. Serum amylase > twice normal (2 to 3 days).
Review: Serum amylase and lipase and urinary trypsinogen and amylase for diagnosis of acute pancreatitis
Test: 6 Serum amylase > twice normal (2 to 3 days)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Keim 1998 8 7 24 214 0.25 [ 0.11, 0.43 ] 0.97 [ 0.94, 0.99 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 7. Serum amylase > twice normal (4 to 5 days).
Review: Serum amylase and lipase and urinary trypsinogen and amylase for diagnosis of acute pancreatitis
Test: 7 Serum amylase > twice normal (4 to 5 days)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Keim 1998 2 15 30 206 0.06 [ 0.01, 0.21 ] 0.93 [ 0.89, 0.96 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 8. Serum amylase > normal.
Review: Serum amylase and lipase and urinary trypsinogen and amylase for diagnosis of acute pancreatitis
Test: 8 Serum amylase > normal
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Keim 1998 30 27 2 194 0.94 [ 0.79, 0.99 ] 0.88 [ 0.83, 0.92 ]
Patt 1966 26 18 5 151 0.84 [ 0.66, 0.95 ] 0.89 [ 0.84, 0.94 ]
Wu 2009 26 13 4 91 0.87 [ 0.69, 0.96 ] 0.88 [ 0.80, 0.93 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 9. Serum amylase > normal (sensitivity analysis excluding studies with incorporation bias).
Review: Serum amylase and lipase and urinary trypsinogen and amylase for diagnosis of acute pancreatitis
Test: 9 Serum amylase > normal (sensitivity analysis excluding studies with incorporation bias)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Keim 1998 30 27 2 194 0.94 [ 0.79, 0.99 ] 0.88 [ 0.83, 0.92 ]
Patt 1966 26 18 5 151 0.84 [ 0.66, 0.95 ] 0.89 [ 0.84, 0.94 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 10. Serum amylase > normal (2 to 3 days).
Review: Serum amylase and lipase and urinary trypsinogen and amylase for diagnosis of acute pancreatitis
Test: 10 Serum amylase > normal (2 to 3 days)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Keim 1998 21 38 11 183 0.66 [ 0.47, 0.81 ] 0.83 [ 0.77, 0.88 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 11. Serum amylase > normal (4 to 5 days).
Review: Serum amylase and lipase and urinary trypsinogen and amylase for diagnosis of acute pancreatitis
Test: 11 Serum amylase > normal (4 to 5 days)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Keim 1998 11 31 21 190 0.34 [ 0.19, 0.53 ] 0.86 [ 0.81, 0.90 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 12. Serum lipase > 3 times normal.
Review: Serum amylase and lipase and urinary trypsinogen and amylase for diagnosis of acute pancreatitis
Test: 12 Serum lipase > 3 times normal
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Abraham 2011 44 5 25 50 0.64 [ 0.51, 0.75 ] 0.91 [ 0.80, 0.97 ]
Chang 2011 21 29 1 3400 0.95 [ 0.77, 1.00 ] 0.99 [ 0.99, 0.99 ]
Mayumi 2012 126 8 24 241 0.84 [ 0.77, 0.89 ] 0.97 [ 0.94, 0.99 ]
Saez 2005 42 3 8 19 0.84 [ 0.71, 0.93 ] 0.86 [ 0.65, 0.97 ]
Viel 1990 15 21 4 43 0.79 [ 0.54, 0.94 ] 0.67 [ 0.54, 0.78 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 13. Serum lipase > 3 times normal (sensitivity analysis excluding studies with incorporation bias).
Review: Serum amylase and lipase and urinary trypsinogen and amylase for diagnosis of acute pancreatitis
Test: 13 Serum lipase > 3 times normal (sensitivity analysis excluding studies with incorporation bias)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Chang 2011 21 29 1 3400 0.95 [ 0.77, 1.00 ] 0.99 [ 0.99, 0.99 ]
Viel 1990 15 21 4 43 0.79 [ 0.54, 0.94 ] 0.67 [ 0.54, 0.78 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 14. Serum lipase > 3 times normal (sensitivity analysis excluding Chang 2011).
Review: Serum amylase and lipase and urinary trypsinogen and amylase for diagnosis of acute pancreatitis
Test: 14 Serum lipase > 3 times normal (sensitivity analysis excluding Chang 2011)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Abraham 2011 44 5 25 50 0.64 [ 0.51, 0.75 ] 0.91 [ 0.80, 0.97 ]
Mayumi 2012 126 8 24 241 0.84 [ 0.77, 0.89 ] 0.97 [ 0.94, 0.99 ]
Saez 2005 42 3 8 19 0.84 [ 0.71, 0.93 ] 0.86 [ 0.65, 0.97 ]
Viel 1990 15 21 4 43 0.79 [ 0.54, 0.94 ] 0.67 [ 0.54, 0.78 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 15. Serum lipase > twice normal.
Review: Serum amylase and lipase and urinary trypsinogen and amylase for diagnosis of acute pancreatitis
Test: 15 Serum lipase > twice normal
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Chang 2011 22 51 0 3378 1.00 [ 0.85, 1.00 ] 0.99 [ 0.98, 0.99 ]
Keim 1998 30 11 2 210 0.94 [ 0.79, 0.99 ] 0.95 [ 0.91, 0.97 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 16. Serum lipase > twice normal (sensitivity analysis excluding Chang 2011).
Review: Serum amylase and lipase and urinary trypsinogen and amylase for diagnosis of acute pancreatitis
Test: 16 Serum lipase > twice normal (sensitivity analysis excluding Chang 2011)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Keim 1998 30 11 2 210 0.94 [ 0.79, 0.99 ] 0.95 [ 0.91, 0.97 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 17. Serum lipase > twice normal (2 to 3 days).
Review: Serum amylase and lipase and urinary trypsinogen and amylase for diagnosis of acute pancreatitis
Test: 17 Serum lipase > twice normal (2 to 3 days)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Keim 1998 22 20 10 201 0.69 [ 0.50, 0.84 ] 0.91 [ 0.86, 0.94 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 18. Serum lipase > twice normal (4 to 5 days).
Review: Serum amylase and lipase and urinary trypsinogen and amylase for diagnosis of acute pancreatitis
Test: 18 Serum lipase > twice normal (4 to 5 days)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Keim 1998 13 35 19 186 0.41 [ 0.24, 0.59 ] 0.84 [ 0.79, 0.89 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 19. Serum lipase > normal.
Review: Serum amylase and lipase and urinary trypsinogen and amylase for diagnosis of acute pancreatitis
Test: 19 Serum lipase > normal
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Keim 1998 32 35 0 186 1.00 [ 0.89, 1.00 ] 0.84 [ 0.79, 0.89 ]
Patt 1966 23 31 8 138 0.74 [ 0.55, 0.88 ] 0.82 [ 0.75, 0.87 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 20. Serum lipase > normal (2 to 3 days).
Review: Serum amylase and lipase and urinary trypsinogen and amylase for diagnosis of acute pancreatitis
Test: 20 Serum lipase > normal (2 to 3 days)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Keim 1998 31 46 1 175 0.97 [ 0.84, 1.00 ] 0.79 [ 0.73, 0.84 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 21. Serum lipase > normal (4 to 5 days).
Review: Serum amylase and lipase and urinary trypsinogen and amylase for diagnosis of acute pancreatitis
Test: 21 Serum lipase > normal (4 to 5 days)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Keim 1998 19 66 13 155 0.59 [ 0.41, 0.76 ] 0.70 [ 0.64, 0.76 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 22. Urinary trypsinogen-2 > 50 ng/mL (Actim Pancreatitis).
Review: Serum amylase and lipase and urinary trypsinogen and amylase for diagnosis of acute pancreatitis
Test: 22 Urinary trypsinogen-2 > 50 ng/mL (Actim Pancreatitis)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Abraham 2011 51 3 18 52 0.74 [ 0.62, 0.84 ] 0.95 [ 0.85, 0.99 ]
Aysan 2008 28 3 22 46 0.56 [ 0.41, 0.70 ] 0.94 [ 0.83, 0.99 ]
Mayumi 2012 107 33 49 223 0.69 [ 0.61, 0.76 ] 0.87 [ 0.82, 0.91 ]
Saez 2005 34 3 16 19 0.68 [ 0.53, 0.80 ] 0.86 [ 0.65, 0.97 ]
Wu 2009 28 8 2 96 0.93 [ 0.78, 0.99 ] 0.92 [ 0.85, 0.97 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 23. Urinary trypsinogen-2 > 50 ng/mL (Actim Pancreatitis - sensitivity analysis).
Review: Serum amylase and lipase and urinary trypsinogen and amylase for diagnosis of acute pancreatitis
Test: 23 Urinary trypsinogen-2 > 50 ng/mL (Actim Pancreatitis - sensitivity analysis)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Abraham 2011 51 3 18 52 0.74 [ 0.62, 0.84 ] 0.95 [ 0.85, 0.99 ]
Mayumi 2012 107 33 49 223 0.69 [ 0.61, 0.76 ] 0.87 [ 0.82, 0.91 ]
Saez 2005 34 3 16 19 0.68 [ 0.53, 0.80 ] 0.86 [ 0.65, 0.97 ]
Wu 2009 28 8 2 96 0.93 [ 0.78, 0.99 ] 0.92 [ 0.85, 0.97 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 24. Urinary trypsinogen-2 > 50 ng/mL (quantitative method).
Review: Serum amylase and lipase and urinary trypsinogen and amylase for diagnosis of acute pancreatitis
Test: 24 Urinary trypsinogen-2 > 50 ng/mL (quantitative method)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Mayumi 2012 111 28 45 228 0.71 [ 0.63, 0.78 ] 0.89 [ 0.85, 0.93 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 25. Urinary trypsinogen-2 only positive or most positive (threshold for this not available).
Review: Serum amylase and lipase and urinary trypsinogen and amylase for diagnosis of acute pancreatitis
Test: 25 Urinary trypsinogen-2 only positive or most positive (threshold for this not available)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Mayumi 2012 93 20 63 236 0.60 [ 0.51, 0.67 ] 0.92 [ 0.88, 0.95 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 26. Urinary amylase > normal (quantitative).
Review: Serum amylase and lipase and urinary trypsinogen and amylase for diagnosis of acute pancreatitis
Test: 26 Urinary amylase > normal (quantitative)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Wu 2009 25 15 5 89 0.83 [ 0.65, 0.94 ] 0.86 [ 0.77, 0.92 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 27. Urinary amylase 1+ (qualitative).
Review: Serum amylase and lipase and urinary trypsinogen and amylase for diagnosis of acute pancreatitis
Test: 27 Urinary amylase 1+ (qualitative)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Burkitt 1987 27 10 14 167 0.66 [ 0.49, 0.80 ] 0.94 [ 0.90, 0.97 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 28. Urinary amylase 2+ (qualitative).
Review: Serum amylase and lipase and urinary trypsinogen and amylase for diagnosis of acute pancreatitis
Test: 28 Urinary amylase 2+ (qualitative)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Burkitt 1987 18 1 23 176 0.44 [ 0.28, 0.60 ] 0.99 [ 0.97, 1.00 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
A D D I T I O N A L T A B L E S
Table 1. Acute pancreatitis classification
Mild acute pancreatitis Moderate acute pancreatitis Severe acute pancreatitis
• No local or systemic complications.
• No organ failure.
• Interstitial oedematous pancreatitis.
• Local or systemic complications
(peripancreatic fluid collection, pancreatic
pseudocyst, necrosis) may be present.
• Transient organ failure (up to 48 hrs)
may be present.
• May be interstitial oedematous
pancreatitis or necrotising pancreatitis.
• Necrotising pancreatitis may be
infected or sterile.
• Local or systemic complications may
be present.
• Persistent organ failure (> 48 hrs)
present.
• May be interstitial oedematous
pancreatitis or necrotising pancreatitis.
• Necrotising pancreatitis may be
infected or sterile.
Table 2. QUADAS-2 classification (acute pancreatitis)
Domain 1: Participant selection Patient sampling Adult patients with acute epigastric or dif-
fuse abdominal pain
Was a consecutive or random sample of pa-
tients enrolled?
Yes: If a consecutive sample or a random
sample of patients with acute epigastric or
diffuse abdominal pain was included in the
study.
No: If a consecutive sample or a random
sample of patients with acute epigastric or
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Table 2. QUADAS-2 classification (acute pancreatitis) (Continued)
diffuse abdominal pain was not included in
the study.
Unclear: If this information was not avail-
able.
Did the study avoid inappropriate exclu-
sions?
Yes: If all patients with acute epigastric
or diffuse abdominal pain suspected to be
acute pancreatitis were included.
No: If the study excluded patients based on
high or lowprobability of acute pancreatitis
(e.g. those with organ failure).
Unclear: If this information was not avail-
able.
Could the selection of participants have in-
troduced bias?
Low risk of bias: If ’yes’ classification for
both of the above two questions
High risk of bias: If ’no’ classification for
either of the above two questions
Unclear risk of bias: If ’unclear’ classifica-
tion for either of the above two questions
but without a ’no’ classification for either
of the above two questions
Participant characteristics and setting Yes: If all patients with acute epigastric
or diffuse abdominal pain suspected to be
acute pancreatitis were included.
No: If a proportion of patients with acute
epigastric or diffuse abdominal pain were
excluded on the basis of the results of an-
other diagnostic test (e.g. an arterial blood
gas analysis performed after the index test)
.
Unclear: If it is not clear whether the pa-
tients have been included on the basis of
the results of another diagnostic test (e.g.
an arterial blood gas analysis performed af-
ter the index test)
Are there concerns that the included partic-
ipants and setting do not match the review
question?
Low concern: If the participant character-
istics and setting is classified as ’yes’
Unclear concern: If the participant charac-
teristics and setting is classified as ’unclear’
High concern: If the participant character-
istics and setting is classified as ’no’
Domain 2: Index test Index test(s) Serum amylase, serum lipase, urinary
trypsinogen-2, urinary amylase
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Table 2. QUADAS-2 classification (acute pancreatitis) (Continued)
Were the index test results interpretedwith-
out knowledge of the results of the refer-
ence standard?
The index test would always be conducted,
though not interpreted before the reference
standard
Yes: If the index test was conducted and in-
terpreted without knowledge of the results
of the reference standard.
No: If the index test was interpreted with
knowledge of the results of the reference
standard.
Unclear: If it was not clear whether the in-
dex test was interpretedwithout knowledge
of the results of the reference standard
If a threshold was used, was it prespecified? Yes: If a prespecified threshold was used.
No: If a prespecified threshold was not
used.
Unclear: If it was not clear whether the
threshold used was prespecified
Could the conduct or interpretation of the
index test have introduced bias?
Low risk of bias: If ’yes’ classification for
both of the above two questions
High risk of bias: If ’no’ classification for
either of the above two questions
Unclear risk of bias: If ’unclear’ classifica-
tion for either of the above two questions
but without a ’no’ classification for either
of the above two questions
Are there concerns that the index test, its
conduct, or interpretation differ from the
review question?
Low concern: If the criteria for positive in-
dex test are clearly stated
High concern: If the criteria for positive
index test are not stated
Domain 3: Target condition and refer-
ence standard
Target condition and reference standard(s) Target condition: acute pancreatitis (mild,
moderately severe, or severe)
While inflammation of the pancreas con-
firmed by biopsy can be considered to be
the gold standard for the diagnosis of acute
pancreatitis, for ethical reasons it is unlikely
to performed in any participant. As a result,
different study authors may use different
reference standards such as radiological fea-
tures of acute pancreatitis or the presence
of organ failure. However, such reference
standards can miss cases of mild acute pan-
creatitis, resulting in an underestimation of
diagnostic test accuracy of the index tests.
We also accepted the consensus conference
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Table 2. QUADAS-2 classification (acute pancreatitis) (Continued)
definition of acute pancreatitis, i.e. when at
least two of the following three features are
present (Banks 2013).
1. Acute onset of persistent, severe
epigastric pain often radiating to the back.
2. Serum lipase activity (or amylase
activity) at least three times greater than
the upper limit of normal.
3. Characteristic findings of acute
pancreatitis on CECT and less commonly
MRI or transabdominal ultrasonography.
We accepted any of the following used
alone or in combination as reference stan-
dards: biopsy, radiological features of acute
pancreatitis, laparotomy, autopsy, organ
failure, or the consensus conference defini-
tion (including or excluding the index test
being evaluated). In terms of ranking the
reference standards, we considered biopsy
as the best reference standard (although for
ethical reasons it is unlikely to have been
performed in any participant) followed by
the consensus definition of acute pancre-
atitis, radiological, surgical, or autopsy fea-
tures of acute pancreatitis, or the presence
of organ failure, in that order
Is the reference standard likely to correctly
classify the target condition?
Yes: If histological confirmation of acute
pancreatitis is obtained or the consensus
definition of acute pancreatitis is used.
No: If the reference standard is radiological
confirmation or organ failure.
Unclear: If the reference standard was not
adequately described
Is the reference standard independent of the
index test?
Yes: If the index test was not part of the
reference standard.
No: If the index test was part of the refer-
ence standard.
Unclear: If it was not clear whether the in-
dex test was part of the reference standard.
As anticipated, we classified all studies in-
cluded in the review as ’yes’ or ’no’ for this
item
Were the reference standard results inter-
preted without knowledge of the results of
the index tests?
Yes: If the reference standard was inter-
preted without knowledge of the results of
the index test.
No: If the reference standard was inter-
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Table 2. QUADAS-2 classification (acute pancreatitis) (Continued)
preted with knowledge of the results of the
index test.
Unclear: If it was not clear if the reference
standard was interpreted without knowl-
edge of the results of the index test
Could the reference standard, its conduct,
or its interpretation have introduced bias?
Low risk of bias: If ’yes’ classification for all
of the above three questions
High risk of bias: If ’no’ classification for
any of the above three questions
Unclear risk of bias: If ’unclear’ classifica-
tion for any of the above three questions
but without a ’no’ classification for any of
the above three questions
Are there concerns that the target condition
as defined by the reference standard does
not match the question?
As anticipated, we classified all of the in-
cluded studies as ’low concern’ based on the
inclusion criteria for this review
Domain 4: Flow and timing Flow and timing Patients may have complete resolution of
acute pancreatitis if they had acute pancre-
atitis, or may have an episode of acute pan-
creatitis if they did not have acute pancre-
atitis if the interval between the index test
and reference standard is long
Was there an appropriate interval between
index test and reference standard?
Yes: If the time interval between index test
and reference standard was less than one
week.
No: If the time interval between index test
and reference standard was more than one
week.
Unclear: If the time interval between index
test and reference standard was unclear
Did all participants receive a reference stan-
dard?
Yes: If all participants received a reference
standard.
No: If some participants did not receive a
reference standard. Such studies were ex-
cluded.
Unclear: If it was not clear whether all
participants received a reference standard.
Such studies were excluded
As anticipated, we classified all studies in-
cluded in the review as ’yes’ for this item
Did all participants receive the same refer-
ence standard?
Yes: If all participants received the same ref-
erence standard (we anticipate that all stud-
ies will be classified as ’yes’).
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Table 2. QUADAS-2 classification (acute pancreatitis) (Continued)
No: If different participants received differ-
ent reference standards
Unclear: If this information was not clear.
Were all participants included in the anal-
ysis?
Yes: If all participants were included in the
analysis irrespective of whether the results
were interpretable.
No: If some participants were excluded
from the analysis due to uninterpretable re-
sults.
Unclear: If this information was not clear.
Could the patient flow have introduced
bias?
Low risk of bias: If ’yes’ classification for all
of the above four questions
High risk of bias: If ’no’ classification for
any of the above four questions
Unclear risk of bias: If ’unclear’ classifica-
tion for any of the above four questions but
without a ’no’ classification for any of the
above four questions
CECT: contrast-enhanced computed tomography
MRI: magnetic resonance imaging
Table 3. Serum amylase at different thresholds and different times
Index test Sensitivity Specificity Post-
test proba-
bility of a
positive test
1
Post-test
probabil-
ity of a neg-
ative test1
Number
of false pos-
itives per
100 peo-
ple having a
positive test
Number of
false nega-
tives per
100
people hav-
ing a nega-
tive test
Num-
ber of stud-
ies (Num-
ber of par-
ticipants)
Risk of bias
/ Applica-
bility con-
cerns / In-
consistency
Serum amy-
lase
(threshold: >
3 times nor-
mal) (on ad-
mission)
0.71 (95%
CI 0.65 to 0.
77)
0.99 (95%
CI 0.99 to 0.
99)
95.4%
(95% CI 93.
4% to 96.
8%)
7.8% (95%
CI 6.4% to
9.5%)
5 (95% CI 3
to 7)
8 (95% CI 6
to 9)
4 (4056) High / High
/ No
Serum amy-
lase
(threshold: >
3 times nor-
mal) (on ad-
mission (ex-
clud-
0.72 (95%
CI 0.59 to 0.
82)
0.93 (95%
CI 0.66 to 0.
99)
74.0%
(95% CI 33.
4% to 94.
1%)
8.1% (95%
CI 5.4% to
12.1%)
26 (95% CI
6 to 67)
8 (95% CI 5
to 12)
3 (605) Un-
clear / Low /
Moderate
115Serum amylase and lipase and urinary trypsinogen and amylase for diagnosis of acute pancreatitis (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Table 3. Serum amylase at different thresholds and different times (Continued)
ing Chang
2011))
Serum amy-
lase
(threshold: >
3 times nor-
mal) (on ad-
mission (ex-
cluding
studies with
incorpora-
tion bias))
0.64 (95%
CI 0.41 to 0.
82)
0.99 (95%
CI 0.99 to 1.
00)
97.1%
(95% CI 95.
1% to 98.
3%)
9.7% (95%
CI 5.8% to
15.7%)
3 (95% CI 2
to 5)
10 (95% CI
6 to 16)
1 (3451) High / High
/ Not appli-
cable
Serum amy-
lase (thresh-
old: > twice
normal) (on
admission)
0.76 (95%
CI 0.57 to 0.
88)
0.99 (95%
CI 0.98 to 0.
99)
95.3%
(95% CI 92.
6% to 97.
1%)
6.6% (95%
CI 3.5% to
12.2%)
5 (95% CI 3
to 7)
7 (95% CI 4
to 12)
2 (3704) High / High
/ No
Serum amy-
lase (thresh-
old:
> twice nor-
mal) (on ad-
mission (ex-
clud-
ing Chang
2011))
0.72 (95%
CI 0.53 to 0.
86)
0.98 (95%
CI 0.95 to 0.
99)
92.1%
(95% CI 81.
1% to 96.
9%)
7.7% (95%
CI 4.6% to
12.7%)
8 (95% CI 3
to 19)
8 (95% CI 5
to 13)
1 (253) High / Un-
clear / Not
applicable
Serum amy-
lase (thresh-
old: > twice
normal)
(2 to 3 days
after admis-
sion)
0.25 (95%
CI 0.12 to 0.
44)
0.97 (95%
CI 0.93 to 0.
99)
69.8%
(95% CI 47.
3% to 85.
6%)
18.5%
(95% CI 15.
6% to 21.
7%)
30 (95% CI
14 to 53)
18 (95% CI
16 to 22)
1 (253) High / Un-
clear / Not
applicable
Serum amy-
lase (thresh-
old: > twice
normal)
(4 to 5 days
after admis-
sion)
0.06 (95%
CI 0.01 to 0.
22)
0.93 (95%
CI 0.89 to 0.
96)
21.
2%(95%CI
6.1% to 52.
9%)
22.7%
(95% CI 21.
1% to 24.
5%)
79 (95% CI
47 to 94)
23 (95% CI
21 to 24)
1 (253) High / Un-
clear / Not
applicable
Serum amy-
lase (thresh-
old: > nor-
0.88 (95%
CI 0.77 to 0.
94)
0.88 (95%
CI 0.84 to 0.
91)
68.7%
(95% CI 61.
6% to 75.
3 (587) High / Un-
clear / No
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Table 3. Serum amylase at different thresholds and different times (Continued)
mal) (on ad-
mission)
1%)
Serum amy-
lase (thresh-
old: > nor-
mal) (on ad-
mission (ex-
cluding
studies with
incorpora-
tion bias))
0.89 (95%
CI 0.72 to 0.
96)
0.88 (95%
CI 0.83 to 0.
92)
69.3%
(95% CI 60.
0% to 77.
2%)
3.5% (95%
CI 1.3% to
9.0%)
31 (95% CI
23 to 40)
4 (95% CI 1
to 9)
2 (453) High / Un-
clear / No
Serum amy-
lase (thresh-
old: > nor-
mal) (2 to
3 days after
admission)
0.66 (95%
CI 0.47 to 0.
81)
0.83 (95%
CI 0.77 to 0.
87)
52.8%
(95% CI 43.
2% to 62.
1%)
10.
8%(95%CI
7.0% to 16.
4%)
47 (95% CI
38 to 57)
11 (95% CI
7 to 16)
1 (253) High / Un-
clear / Not
applicable
Serum amy-
lase (thresh-
old: > nor-
mal) (4 to
5 days after
admission)
0.34 (95%
CI 0.19 to 0.
53)
0.86 (95%
CI 0.81 to 0.
90)
41.8%
(95% CI 28.
7% to 56.
1%)
18.3%
(95% CI 14.
7% to 22.
4%)
58 (95% CI
44 to 71)
18 (95% CI
15 to 22)
1 (253) High / Un-
clear / Not
applicable
CI: confidence interval
1The post-test probabilities were calculated at the median pre-test probability of 22.6%.
Table 4. Serum lipase at different thresholds and different times
Index test Sensitivity Specificity Post-
test proba-
bility of a
positive test
1
Post-test
probabil-
ity of a neg-
ative test1
Number
of false pos-
itives per
100 peo-
ple having a
positive test
Number of
false nega-
tives per
100
people hav-
ing a nega-
tive test
Num-
ber of stud-
ies (Num-
ber of par-
ticipants)
Risk of bias
/ Applica-
bility con-
cerns / In-
consistency
Serum lipase
(threshold: >
3 times nor-
mal) (on ad-
mission)
0.80 (95%
CI 0.73 to 0.
86)
0.93 (95%
CI 0.00 to 1.
00)
78.3%
(95% CI 0.
0% to 100.
0%)
5.9% (95%
CI 2.3% to
14.4%)
22 (95% CI
0 to 100)
6 (95% CI 2
to 14)
5 (4129) High / High
/ Moderate
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Table 4. Serum lipase at different thresholds and different times (Continued)
Serum lipase
(threshold: >
3 times nor-
mal) (on ad-
mission (ex-
clud-
ing Chang
2011))
0.79 (95%
CI 0.54 to 0.
92)
0.89 (95%
CI 0.46 to 0.
99)
68.1%
(95% CI 21.
4% to 94.
3%)
6.6% (95%
CI 2.7% to
15.1%)
32 (95% CI
6 to 79)
7 (95% CI 3
to 15)
4 (678) Un-
clear / Low /
Moderate
Serum lipase
(threshold: >
3 times nor-
mal) (on ad-
mission (ex-
cluding
studies with
incorpora-
tion bias))
0.88 (95%
CI 0.02 to 1.
00)
0.94 (95%
CI 0.00 to 1.
00)
81.2%
(95% CI 0.
0% to 100.
0%)
3.7% (95%
CI 0.0% to
99.2%)
19 (95% CI
0 to 100)
4 (95% CI 0
to 99)
2 (3534) High / High
/ High
Serum lipase
(threshold:
> twice nor-
mal) (on ad-
mission)
0.96 (95%
CI 0.78 to 0.
99)
0.98 (95%
CI 0.98 to 0.
99)
94.3%
(95% CI 92.
1% to 96.
0%)
1.1% (95%
CI 0.2% to
7.0%)
6 (95% CI 4
to 8)
1 (95% CI 0
to 7)
2 (3704) High / High
/ No
Serum lipase
(threshold:
> twice nor-
mal) (on ad-
mission (ex-
clud-
ing Chang
2011))
0.94 (95%
CI 0.78 to 0.
99)
0.95 (95%
CI 0.91 to 0.
97)
84.6%
(95% CI 75.
5% to 90.
8%)
1.9% (95%
CI 0.5% to
6.9%)
15 (95% CI
9 to 25)
2 (95% CI 1
to 7)
1 (253) High / Un-
clear / Not
applicable
Serum lipase
(threshold:
> twice nor-
mal) (2 to
3 days after
admission)
0.69 (95%
CI 0.50 to 0.
83)
0.91 (95%
CI 0.86 to 0.
94)
69.0%
(95% CI 57.
9% to 78.
2%)
9.1% (95%
CI 5.7% to
14.4%)
31 (95% CI
22 to 42)
9 (95% CI 6
to 14)
1 (253) High / Un-
clear / Not
applicable
Serum lipase
(threshold:
> twice nor-
mal) (4 to
5 days after
admission)
0.41 (95%
CI 0.24 to 0.
59)
0.84 (95%
CI 0.79 to 0.
89)
42.9%
(95% CI 30.
9% to 55.
7%)
17.1%
(95% CI 13.
4% to 21.
7%)
57 (95% CI
44 to 69)
17 (95% CI
13 to 22)
1 (253) High / Un-
clear / Not
applicable
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Table 4. Serum lipase at different thresholds and different times (Continued)
Serum lipase
(threshold: >
normal) (on
admission)
0.96 (95%
CI 0.00 to 1.
00)
0.83 (95%
CI 0.47 to 0.
96)
62.5%
(95% CI 21.
7% to 90.
9%)
1.3% (95%
CI 0.0% to
100.0%)
38 (95% CI
9 to 78)
1 (95% CI 0
to 100)
2 (453) High / Un-
clear / Hight
Serum lipase
(threshold: >
normal)
(2 to 3 days
after admis-
sion)
0.97 (95%
CI 0.82 to 1.
00)
0.79 (95%
CI 0.73 to 0.
84)
57.7%
(95% CI 51.
1% to 64.
0%)
1.1% (95%
CI 0.2% to
7.4%)
42 (95% CI
36 to 49)
1 (95% CI 0
to 7)
1 (253) High / Un-
clear / Not
applicable
Serum lipase
(threshold: >
normal)
(4 to 5 days
after admis-
sion)
0.59 (95%
CI 0.41 to 0.
76)
0.70 (95%
CI 0.64 to 0.
76)
36.8%
(95% CI 29.
1% to 45.
2%)
14.5%
(95% CI 10.
0% to 20.
6%)
63 (95% CI
55 to 71)
14 (95% CI
10 to 21)
1 (253) High / Un-
clear / Not
applicable
CI: confidence interval
1The post-test probabilities were calculated at the median pre-test probability of 22.6%.
Table 5. Urinary tests
Index test Sensitivity Specificity Post-
test proba-
bility of a
positive test
1
Post-test
probabil-
ity of a neg-
ative test1
Number
of false pos-
itives per
100 peo-
ple having a
positive test
Number of
false nega-
tives per
100
people hav-
ing a nega-
tive test
Num-
ber of stud-
ies (Num-
ber of par-
ticipants)
Risk of bias
/ Applica-
bility con-
cerns / In-
consistency
Urinary
trypsino-
gen-
2 (threshold:
Actim Pan-
creatitis - all
studies; > 50
ng/mL) (on
admission)
0.72 (95%
CI 0.56 to 0.
84)
0.90 (95%
CI 0.85 to 0.
93)
67.2%
(95% CI 57.
3% to 75.
7%)
8.4% (95%
CI 5.2% to
13.3%)
33 (95% CI
24 to 43)
8 (95% CI 5
to 13)
5 (841) High / Un-
clear / Mod-
erate
Urinary
trypsino-
gen-
2 (threshold:
Ac-
tim Pancre-
0.74 (95%
CI 0.56 to 0.
87)
0.89 (95%
CI 0.84 to 0.
93)
66.9%
(95% CI 55.
4% to 76.
7%)
7.7% (95%
CI 4.3% to
13.5%)
33 (95% CI
23 to 45)
8 (95% CI 4
to 14)
4 (742) High / Un-
clear / Mod-
erate
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Table 5. Urinary tests (Continued)
atitis - sensi-
tivity analy-
sis; > 50 ng/
mL) (on ad-
mission)
Urinary
trypsino-
gen-
2 (quantita-
tive)
(threshold: >
50 ng/mL)
(on admis-
sion)
0.71 (95%
CI 0.63 to 0.
78)
0.89 (95%
CI 0.84 to 0.
92)
65.6%
(95% CI 57.
0% to 73.
3%)
8.7% (95%
CI 6.9% to
10.9%)
34 (95% CI
27 to 43)
9 (95% CI 7
to 11)
1 (412) High / Low /
Not applica-
ble
Urinary
trypsino-
gen-
2 (threshold:
only
+ or most
positive - the
threshold
for this was
not avail-
able) (on ad-
mission)
0.60 (95%
CI 0.51 to 0.
67)
0.92 (95%
CI 0.88 to 0.
95)
69.1%
(95% CI 59.
0% to 77.
6%)
11.
4%(95%CI
9.6% to 13.
5%)
31 (95% CI
22 to 41)
11 (95% CI
10 to 13)
1 (412) High / Low /
Not applica-
ble
Urinary
amy-
lase (quanti-
tative)
(threshold:
above nor-
mal) (on ad-
mission)
0.83 (95%
CI 0.65 to 0.
94)
0.86 (95%
CI 0.77 to 0.
91)
62.8%
(95% CI 50.
8% to 73.
5%)
5.4% (95%
CI 2.5% to
11.3%)
37 (95% CI
27 to 49)
5 (95% CI 2
to 11)
1 (134) Unclear
/ Unclear /
Not applica-
ble
Urinary
amylase
(qualitative)
(threshold: 1
plus) (on ad-
mission)
0.66 (95%
CI 0.49 to 0.
79)
0.94 (95%
CI 0.90 to 0.
97)
77.3%
(95% CI 64.
2% to 86.
6%)
9.6% (95%
CI 6.5% to
14.0%)
23 (95% CI
13 to 36)
10 (95% CI
6 to 14)
1 (218) High / High
/ Not appli-
cable
Urinary
amylase
(qualitative)
(threshold: 2
0.44 (95%
CI 0.29 to 0.
60)
0.99 (95%
CI 0.96 to 1.
00)
95.8%
(95% CI 75.
8% to 99.
4%)
14.2%
(95% CI 11.
2% to 17.
8%)
4 (95% CI 1
to 24)
14 (95% CI
11 to 18)
1 (218) High / High
/ Not appli-
cable
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Table 5. Urinary tests (Continued)
plus) (on ad-
mission)
CI: confidence interval
1The post-test probabilities were calculated at the median pre-test probability of 22.6%.
A P P E N D I C E S
Appendix 1. Glossary of terms
Acute: sudden onset.
Adipose: fat.
Aetiology: cause.
Autodigestion: breaking down of the same organ that secretes the substance.
Cholecystectomy: removal of the gallbladder.
Cholecystitis: inflammation of the gallbladder.
Debridement: surgical removal of damaged, dead, or infected tissue; in this context, identical with necrosectomy.
Dyspepsia: discomfort in the upper abdomen or chest that may be described as gas, a feeling of fullness, or burning.
Endoscopic: using an endoscope, a flexible tube with a light and camera attached to it, to view the inner aspects of the food pipe,
stomach, and upper small intestine.
Epigastric: upper central abdomen.
Gastrointestinal: relating to the stomach and the intestines.
Heterogeneity: differences between studies.
Histological: by examination of the tissue under a microscope.
Hyperamylasaemia: excess amylase in circulation.
Interstitial: small, narrow spaces between tissues or parts of an organ.
Intraperitoneal: inside the abdominal cavity.
Isoforms: two or more functionally similar proteins that have a similar but not identical composition.
Laparotomy: surgical incision into the abdominal cavity, for diagnosis or treatment of intra-abdominal diseases.
Lymphatics: vessels carrying lymph in the body.
Magnetic resonance cholangiopancreatography: medical imaging technique that uses magnetic resonance imaging (use of magnetic
field to differentiate between different structures) to visualise the biliary and pancreatic ducts in a non-invasive manner.
Methodological: related to methods by which the study was conducted (in this context).
Mortality rate: death rate.
Necrosectomy: removal of dead tissue.
Necrosis: death and decomposition of living tissue usually caused by lack of blood supply, but can be the result of other pathological
insult.
Necrotising: presence of necrosis.
Oedema: swelling.
Oedematous: tissue with an excess of interstitial fluid.
Pancreatic ductal system: tubular system that transports the pancreatic juice secreted by the pancreatic cells to the small intestine.
Pancreatic pseudocysts: fluid collections in the pancreas or the tissues surrounding the pancreas, enclosed by a well-defined wall and
containing only fluid with little or no solid material.
Parenchyma: functional parts of an organ.
Percutaneous: through the skin.
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Percutaneous drainage: drainage carried out by insertion of drain from the external surface of the body, usually guided by an ultrasound
or computed tomography (CT) scan.
Peripancreatic tissues: tissues surrounding the pancreas.
Peritonitis: inflammation of the peritoneum (the inner lining of the abdominal wall).
Prognosis: health outcome.
Pulse oximetry: non-invasive method of measuring the oxygen level (oxygen saturation) of the blood, usually using infrared.
Radiating to the back: pain in front going to the back (in this context).
Retroperitoneal: behind the abdominal cavity.
SAS code: set of instructions for using an ’SAS’ program to perform statistical analysis.
Sphincterotomy: partial division of the sphincter of Oddi, a circular band of muscle at the junction of the biliary tree (tubes that
conduct bile from the liver to the small intestine) and pancreatic duct (tubes that conduct pancreatic juice into the second part of the
duodenum).
Transabdominal: through the abdominal cavity.
Transluminal: through the lumen (inner cavity of a tubular structure).
Transperitoneal: through the abdominal cavity.
Triage: determining whether the patient requires further tests (in this context).
Ultrasonography: using high-frequency sound to view internal structures of the body (in this context).
Appendix 2. MEDLINE search strategy
1. Pancreatitis, Acute Necrotizing/
2. Pancreatitis/et
3. Pancreas/ab, pa, pp
4. (acute adj3 pancrea*).mp.
5. (necro* adj3 pancrea*).mp.
6. (inflam* adj3 pancrea*).mp.
7. ((interstitial or edema* or oedema*) adj2 pancrea*).mp.
8. 1 or 2 or 3 or 4 or 5 or 6 or 7
9. exp Amylases/ or exp Lipase/ or exp Trypsinogen/
10. (amylase or lipase or trypsinogen or hyperamylasaemia or hyperamylasemia).mp.
11. exp C-Reactive Protein/
12. (“c-reactive protein” or “c reactive protein” or CRP).mp.
13. procalcitonin.mp.
14. exp L-Lactate Dehydrogenase/
15. (“lactate dehydrogenase” or LDH).mp.
16. 9 or 10 or 11 or 12 or 13 or 14 or 15
17. 8 and 16
Appendix 3. Embase search strategy
1. acute hemorrhagic pancreatitis/
2. Pancreatitis/et
3. acute pancreatitis/
4. (acute adj3 pancrea*).mp.
5. (necro* adj3 pancrea*).mp.
6. (inflam* adj3 pancrea*).mp.
7. ((interstitial or edema* or oedema*) adj2 pancrea*).mp.
8. 1 or 2 or 3 or 4 or 5 or 6 or 7
9. exp amylase/
10. exp triacylglycerol lipase/
11. exp trypsinogen/
12. (amylase or lipase or trypsinogen or hyperamylasaemia or hyperamylasemia).mp.
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13. exp C reactive protein/
14. (“c-reactive protein” or “c reactive protein” or CRP).mp.
15. exp procalcitonin/
16. procalcitonin.mp.
17. exp lactate dehydrogenase/
18. (“lactate dehydrogenase” or LDH).mp.
19. 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18
20. 8 and 19
Appendix 4. Science Citation Index and Conference Proceedings Citation Index-Science search
strategy
# 1 TS=((acute or necro* or inflam* or interstitial or edema* or oedema*) near/3 pancrea*)
# 2 TS=(amylase or lipase or trypsinogen or hyperamylasaemia or hyperamylasemia or “c-reactive protein” or “c reactive protein” or
CRP or procalcitonin or “lactate dehydrogenase” or LDH)
# 3 #2 AND #1
Appendix 5. National Institute for Health Research - HTA and DARE search strategy
acute pancreatitis
Appendix 6. Zetoc search strategy
Each of the following lines will be searched separately. since the Boolean operator ’or’ is not available for searching Zetoc database.
1. acute pancreatitis amylase
2. acute pancreatitis lipase
3. acute pancreatitis trypsinogen
4. acute pancreatitis hyperamylasaemia
5. acute pancreatitis hyperamylasemia
6. acute pancreatitis “c-reactive protein”
7. acute pancreatitis “c reactive protein”
8. acute pancreatitis CRP
9. acute pancreatitis procalcitonin
10. acute pancreatitis “lactate dehydrogenase”
11. acute pancreatitis LDH
Appendix 7. WHO ICTRP search strategy
Title: (amylase or lipase or trypsinogen or hyperamylasaemia or hyperamylasemia or “c-reactive protein” or “c reactive protein” or CRP
or procalcitonin or “lactate dehydrogenase” or LDH)
Condition: acute pancreatitis
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Appendix 8. ClinicalTrials.gov search strategy
amylase OR lipase OR trypsinogen OR hyperamylasaemia OR hyperamylasemia OR “c-reactive protein” OR “c reactive protein” OR
CRP OR procalcitonin OR “lactate dehydrogenase” OR LDH | acute pancreatitis
Appendix 9. SAS code used for fitting different models
data DiagnosticTestMetaAnalysis;
input Study˙id TP FP FN TN;
/* Modify the data for the different tests*/
datalines;
1 52 7 17 48
2 14 19 8 3410
3 109 9 47 244
4 37 3 13 19
run;
/* Modify the dataset for the bivariate analysis */
data dt;
set DiagnosticTestMetaAnalysis;
sens=1; spec=0; true=tp; n=tp+fn; output;
sens=0; spec=1; true=tn; n=tn+fp; output;
run;
/* Ensure that both records for a study are clustered together */
proc sort data=dt;
by study˙id ;
run;
/* MODEL 1 */
/* Save NLMIXED output in the following datasets*/
ods output ParameterEstimates=pet1 FitStatistics=fitt1 additionalestimates=addest1
CovMatParmEst=covparmestt1 ConvergenceStatus=convgstatt1;
/* Run the bivariate random effects logistic regression model for sensitivity and specificity */
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/* The cov option requests that a covariance matrix is printed for all model parameter estimates.*/
proc nlmixed data=dt cov tech=quanew lis=5;
parms msens=2 mspec=1 s2usens=0 s2uspec=0 covsesp=0;
logitp=(msens+usens)*sens+(mspec+uspec)*spec;
p = exp(logitp)/(1+exp(logitp));
model true ~ binomial(n,p);
random usens uspec ~ normal([0,0],[s2usens,covsesp,s2uspec]) subject=study˙id out=randeffs;
estimate ’logLR+’ log((exp(msens)/(1+exp(msens)))/(1-(exp(mspec)/(1+exp(mspec)))));
estimate ’logLR-’ log((1-(exp(msens)/(1+exp(msens))))/(exp(mspec)/(1+exp(mspec))));
run;
/* Obtain summary sens and spec from the model 1*/
/* change the number if this is for a different model*/
data summary1;
set pet1;
if parameter = ’msens’ then name = ’Sensitivity’;
else if parameter = ’mspec’ then name = ’Specificity’;
if parameter = ’msens’ or parameter =’mspec’ then summary=100 * exp(estimate)/(1 + exp(estimate));
if parameter = ’msens’ or parameter =’mspec’ then summlower=100 * exp(lower)/(1 + exp(lower));
if parameter = ’msens’ or parameter =’mspec’ then summupper=100 *exp(upper)/(1 + exp(upper));
output;
run;
/* Obtain summary LR from the model 1 */
data summaryLR1;
set addest1;
summary=exp(estimate);
summlower=exp(lower);
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summupper=exp(upper);
output;
run;
PROC EXPORT DATA= WORK.SUMMARY1
/* Modify the path for this outfile and the other outfiles */
OUTFILE = “C:\Users\kurinchi2k\Downloads\Acute pancreatitis DTAR\SA˙3\SASFile\IndeterminatesExcluded\Summary1.csv”
DBMS=CSV REPLACE;
RUN;
/* Export parameter estimates table */
PROC EXPORT DATA= WORK.pet1
OUTFILE = “C:\Users\kurinchi2k\Downloads\Acute pancreatitis DTAR\SA˙3\SASFile\IndeterminatesExcluded\Parameter esti-
mates1.csv”
DBMS=CSV REPLACE;
RUN;
/* Export the summary LR as an Excel .csv file */
PROC EXPORT DATA= WORK.SUMMARYLR1
OUTFILE = “C:\Users\kurinchi2k\Downloads\Acute pancreatitis DTAR\SA˙3\SASFile\IndeterminatesExcluded\SummaryLR1.csv”
DBMS=CSV REPLACE;
RUN;
/* Export Fit statistics table */
PROC EXPORT DATA= WORK.fitt1
OUTFILE = “C:\Users\kurinchi2k\Downloads\Acute pancreatitis DTAR\SA˙3\SASFile\IndeterminatesExcluded\Fit statistics1.csv”
DBMS=CSV REPLACE;
RUN;
/* Export covariance parameter estimates table */
PROC EXPORT DATA= WORK.covparmestt1
OUTFILE = “C:\Users\kurinchi2k\Downloads\Acute pancreatitis DTAR\SA˙3\SASFile\IndeterminatesExcluded\Covariance param-
eter estimates1.csv”
DBMS=CSV REPLACE;
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RUN;
/* MODEL 2 */
ods output ParameterEstimates=pet2 FitStatistics=fitt2 additionalestimates=addest2 CovMatParmEst=covparmestt2 ConvergenceSta-
tus=convgstatt2;
/* Run univariate random effects logistic regression models for sensitivity and specificity, i.e., ignore the correlation */
proc nlmixed data=dt cov tech=quanew lis=5;
parms msens=2 mspec=1 s2usens=0 s2uspec=0 ;
logitp=(msens+usens)*sens+(mspec+uspec)*spec;
p = exp(logitp)/(1+exp(logitp));
model true ~ binomial(n,p);
random usens uspec ~ normal([0,0],[s2usens,0,s2uspec]) subject=study˙id out=randeffs;
estimate ’logLR+’ log((exp(msens)/(1+exp(msens)))/(1-(exp(mspec)/(1+exp(mspec)))));
estimate ’logLR-’ log((1-(exp(msens)/(1+exp(msens))))/(exp(mspec)/(1+exp(mspec))));
run;
/* Obtain summary sens and spec from the model 2*/
/* change the number if this is for a different model*/
data summary2;
set pet2;
if parameter = ’msens’ then name = ’Sensitivity’;
else if parameter = ’mspec’ then name = ’Specificity’;
if parameter = ’msens’ or parameter =’mspec’ then summary=100 * exp(estimate)/(1 + exp(estimate));
if parameter = ’msens’ or parameter =’mspec’ then summlower=100 * exp(lower)/(1 + exp(lower));
if parameter = ’msens’ or parameter =’mspec’ then summupper=100 *exp(upper)/(1 + exp(upper));
output;
run;
/* Obtain summary LR from the model 2 */
data summaryLR2;
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set addest2;
summary=exp(estimate);
summlower=exp(lower);
summupper=exp(upper);
output;
run;
PROC EXPORT DATA= WORK.SUMMARY2
OUTFILE = “C:\Users\kurinchi2k\Downloads\Acute pancreatitis DTAR\SA˙3\SASFile\IndeterminatesExcluded\Summary2.csv”
DBMS=CSV REPLACE;
RUN;
/* Export parameter estimates table */
PROC EXPORT DATA= WORK.pet2
OUTFILE = “C:\Users\kurinchi2k\Downloads\Acute pancreatitis DTAR\SA˙3\SASFile\IndeterminatesExcluded\Parameter esti-
mates2.csv”
DBMS=CSV REPLACE;
RUN;
/* Export the summary LR as an Excel .csv file */
PROC EXPORT DATA= WORK.SUMMARYLR2
OUTFILE = “C:\Users\kurinchi2k\Downloads\Acute pancreatitis DTAR\SA˙3\SASFile\IndeterminatesExcluded\SummaryLR2.csv”
DBMS=CSV REPLACE;
RUN;
/* Export Fit statistics table */
PROC EXPORT DATA= WORK.fitt2
OUTFILE = “C:\Users\kurinchi2k\Downloads\Acute pancreatitis DTAR\SA˙3\SASFile\IndeterminatesExcluded\Fit statistics2.csv”
DBMS=CSV REPLACE;
RUN;
/* Export covariance parameter estimates table */
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PROC EXPORT DATA= WORK.covparmestt2
OUTFILE = “C:\Users\kurinchi2k\Downloads\Acute pancreatitis DTAR\SA˙3\SASFile\IndeterminatesExcluded\Covariance param-
eter estimates2.csv”
DBMS=CSV REPLACE;
RUN;
/* MODEL 3 */
ods output ParameterEstimates=pet3 FitStatistics=fitt3 additionalestimates=addest3
CovMatParmEst=covparmestt3 ConvergenceStatus=convgstatt3 additionalestimates=addest3;
/* Run random effects logistic regression model for sensitivity and fixed model for specificity */
proc nlmixed data=dt cov tech=quanew lis=5 qpoints=10;
parms msens=2 mspec=1 s2usens=0 ;
logitp=(msens+usens)*sens+(mspec)*spec;
p = exp(logitp)/(1+exp(logitp));
model true ~ binomial(n,p);
random usens ~ normal([0],[s2usens]) subject=study˙id out=randeffs;
estimate ’logLR+’ log((exp(msens)/(1+exp(msens)))/(1-(exp(mspec)/(1+exp(mspec)))));
estimate ’logLR-’ log((1-(exp(msens)/(1+exp(msens))))/(exp(mspec)/(1+exp(mspec))));
run;
/* Obtain summary sens and spec from the model 3*/
/* change the number if this is for a different model*/
data summary3;
set pet3;
if parameter = ’msens’ then name = ’Sensitivity’;
else if parameter = ’mspec’ then name = ’Specificity’;
if parameter = ’msens’ or parameter =’mspec’ then summary=100 * exp(estimate)/(1 + exp(estimate));
if parameter = ’msens’ or parameter =’mspec’ then summlower=100 * exp(lower)/(1 + exp(lower));
if parameter = ’msens’ or parameter =’mspec’ then summupper=100 *exp(upper)/(1 + exp(upper));
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output;
run;
/* Obtain summary LR from the model 3 */
data summaryLR3;
set addest3;
summary=exp(estimate);
summlower=exp(lower);
summupper=exp(upper);
output;
run;
PROC EXPORT DATA= WORK.SUMMARY3
OUTFILE = “C:\Users\kurinchi2k\Downloads\Acute pancreatitis DTAR\SA˙3\SASFile\IndeterminatesExcluded\Summary3.csv”
DBMS=CSV REPLACE;
RUN;
/* Export parameter estimates table */
PROC EXPORT DATA= WORK.pet3
OUTFILE = “C:\Users\kurinchi2k\Downloads\Acute pancreatitis DTAR\SA˙3\SASFile\IndeterminatesExcluded\Parameter esti-
mates3.csv”
DBMS=CSV REPLACE;
RUN;
/* Export the summary LR as an Excel .csv file */
PROC EXPORT DATA= WORK.SUMMARYLR3
OUTFILE = “C:\Users\kurinchi2k\Downloads\Acute pancreatitis DTAR\SA˙3\SASFile\IndeterminatesExcluded\SummaryLR3.csv”
DBMS=CSV REPLACE;
RUN;
/* Export Fit statistics table */
PROC EXPORT DATA= WORK.fitt3
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OUTFILE = “C:\Users\kurinchi2k\Downloads\Acute pancreatitis DTAR\SA˙3\SASFile\IndeterminatesExcluded\Fit statistics3.csv”
DBMS=CSV REPLACE;
RUN;
/* Export covariance parameter estimates table */
PROC EXPORT DATA= WORK.covparmestt3
OUTFILE = “C:\Users\kurinchi2k\Downloads\Acute pancreatitis DTAR\SA˙3\SASFile\IndeterminatesExcluded\Covariance param-
eter estimates3.csv”
DBMS=CSV REPLACE;
RUN;
/* MODEL 4 */
ods output ParameterEstimates=pet4 FitStatistics=fitt4 additionalestimates=addest4
CovMatParmEst=covparmestt4 ConvergenceStatus=convgstatt4;
/* Run fixed effect logistic regression model for sensitivity and random effects model for specificity */
proc nlmixed data=dt cov tech=quanew lis=5 qpoints=10;
parms msens=2 mspec=1 s2uspec=0 ;
logitp=(msens)*sens+(mspec+uspec)*spec;
p = exp(logitp)/(1+exp(logitp));
model true ~ binomial(n,p);
random uspec ~ normal([0],[s2uspec]) subject=study˙id out=randeffs;
estimate ’logLR+’ log((exp(msens)/(1+exp(msens)))/(1-(exp(mspec)/(1+exp(mspec)))));
estimate ’logLR-’ log((1-(exp(msens)/(1+exp(msens))))/(exp(mspec)/(1+exp(mspec))));
run;
/* Obtain summary sens and spec from the model 4*/
/* change the number if this is for a different model*/
data summary4;
set pet4;
if parameter = ’msens’ then name = ’Sensitivity’;
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else if parameter = ’mspec’ then name = ’Specificity’;
if parameter = ’msens’ or parameter =’mspec’ then summary=100 * exp(estimate)/(1 + exp(estimate));
if parameter = ’msens’ or parameter =’mspec’ then summlower=100 * exp(lower)/(1 + exp(lower));
if parameter = ’msens’ or parameter =’mspec’ then summupper=100 *exp(upper)/(1 + exp(upper));
output;
run;
/* Obtain summary LR from the model 4 */
data summaryLR4;
set addest4;
summary=exp(estimate);
summlower=exp(lower);
summupper=exp(upper);
output;
run;
PROC EXPORT DATA= WORK.SUMMARY4
OUTFILE = “C:\Users\kurinchi2k\Downloads\Acute pancreatitis DTAR\SA˙3\SASFile\IndeterminatesExcluded\Summary4.csv”
DBMS=CSV REPLACE;
RUN;
/* Export parameter estimates table */
PROC EXPORT DATA= WORK.pet4
OUTFILE = “C:\Users\kurinchi2k\Downloads\Acute pancreatitis DTAR\SA˙3\SASFile\IndeterminatesExcluded\Parameter esti-
mates4.csv”
DBMS=CSV REPLACE;
RUN;
/* Export the summary LR as an Excel .csv file */
PROC EXPORT DATA= WORK.SUMMARYLR4
OUTFILE = “C:\Users\kurinchi2k\Downloads\Acute pancreatitis DTAR\SA˙3\SASFile\IndeterminatesExcluded\SummaryLR4.csv”
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DBMS=CSV REPLACE;
RUN;
/* Export Fit statistics table */
PROC EXPORT DATA= WORK.fitt4
OUTFILE = “C:\Users\kurinchi2k\Downloads\Acute pancreatitis DTAR\SA˙3\SASFile\IndeterminatesExcluded\Fit statistics4.csv”
DBMS=CSV REPLACE;
RUN;
/* Export covariance parameter estimates table */
PROC EXPORT DATA= WORK.covparmestt4
OUTFILE = “C:\Users\kurinchi2k\Downloads\Acute pancreatitis DTAR\SA˙3\SASFile\IndeterminatesExcluded\Covariance param-
eter estimates4.csv”
DBMS=CSV REPLACE;
RUN;
/* MODEL 5 */
ods output ParameterEstimates=pet5 FitStatistics=fitt5 additionalestimates=addest5
CovMatParmEst=covparmestt5 ConvergenceStatus=convgstatt5;
/* Run fixed effect logistic regression model for sensitivity and specificity */
proc nlmixed data=dt cov tech=quanew lis=5 qpoints=10;
parms msens=2 mspec=1;
logitp=(msens)*sens+(mspec)*spec;
p = exp(logitp)/(1+exp(logitp));
model true ~ binomial(n,p);
estimate ’logLR+’ log((exp(msens)/(1+exp(msens)))/(1-(exp(mspec)/(1+exp(mspec)))));
estimate ’logLR-’ log((1-(exp(msens)/(1+exp(msens))))/(exp(mspec)/(1+exp(mspec))));
run;
/* Obtain summary sens and spec from the model 5*/
/* change the number if this is for a different model*/
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data summary5;
set pet5;
if parameter = ’msens’ then name = ’Sensitivity’;
else if parameter = ’mspec’ then name = ’Specificity’;
if parameter = ’msens’ or parameter =’mspec’ then summary=100 * exp(estimate)/(1 + exp(estimate));
if parameter = ’msens’ or parameter =’mspec’ then summlower=100 * exp(lower)/(1 + exp(lower));
if parameter = ’msens’ or parameter =’mspec’ then summupper=100 *exp(upper)/(1 + exp(upper));
output;
run;
/* Obtain summary LR from the model 5 */
data summaryLR5;
set addest5;
summary=exp(estimate);
summlower=exp(lower);
summupper=exp(upper);
output;
run;
PROC EXPORT DATA= WORK.SUMMARY5
OUTFILE = “C:\Users\kurinchi2k\Downloads\Acute pancreatitis DTAR\SA˙3\SASFile\IndeterminatesExcluded\Summary5.csv”
DBMS=CSV REPLACE;
RUN;
/* Export parameter estimates table */
PROC EXPORT DATA= WORK.pet5
OUTFILE = “C:\Users\kurinchi2k\Downloads\Acute pancreatitis DTAR\SA˙3\SASFile\IndeterminatesExcluded\Parameter esti-
mates5.csv”
DBMS=CSV REPLACE;
RUN;
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/* Export the summary LR as an Excel .csv file */
PROC EXPORT DATA= WORK.SUMMARYLR5
OUTFILE = “C:\Users\kurinchi2k\Downloads\Acute pancreatitis DTAR\SA˙3\SASFile\IndeterminatesExcluded\SummaryLR5.csv”
DBMS=CSV REPLACE;
RUN;
/* Export Fit statistics table */
PROC EXPORT DATA= WORK.fitt5
OUTFILE = “C:\Users\kurinchi2k\Downloads\Acute pancreatitis DTAR\SA˙3\SASFile\IndeterminatesExcluded\Fit statistics5.csv”
DBMS=CSV REPLACE;
RUN;
/* Export covariance parameter estimates table */
PROC EXPORT DATA= WORK.covparmestt5
OUTFILE = “C:\Users\kurinchi2k\Downloads\Acute pancreatitis DTAR\SA˙3\SASFile\IndeterminatesExcluded\Covariance param-
eter estimates5.csv”
DBMS=CSV REPLACE;
RUN;
Appendix 10. Model fit for index tests for which meta-analysis was possible
Model fit Bi-
variate random-ef-
fects model taking
correlation into ac-
count
Bivariate random-
effects model ig-
noring correlation
Random-effects
univariate logistic
regression model
for sensitivity and
fixed-effect model
for specificity
Fixed-effect
model for sensitiv-
ity and random-ef-
fects univariate lo-
gistic re-
gression model for
specificity
Fixed-effect model
for both sensitivity
and specificity
Serum amylase
(threshold: > 3 times
normal) (on admis-
sion)
No convergence No convergence No convergence No convergence 86.4
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(Continued)
Serum
amylase (threshold:
> 3 times normal)
(on admission; ex-
cluding studies with
incorporation bias)
No convergence No convergence No convergence 30.9 33.4
Serum amy-
lase (threshold: > 3
times normal) (on
admission; exclud-
ing Chang 2011)
89.9 91.9 178 30.9 33.4
Serum amylase
(threshold: > twice
normal) (on admis-
sion)
No convergence No convergence No convergence 30.8 17.1
Serum
amylase (threshold:
> normal) (on ad-
mission)
No convergence No convergence No convergence 30.8 24.9
Serum
amylase (threshold:
> normal) (on ad-
mission)
No convergence No convergence No convergence No convergence 17.3
Serum lipase
(threshold: > 3 times
normal) (on admis-
sion)
89.9 91.9 178 89.3 183.5
Serum
lipase (threshold: >
3 times normal) (on
admission; exclud-
ing studies with in-
corporation bias)
No convergence No convergence 125.7 33.2 125.7
Serum
lipase (threshold: >
3 times normal) (on
admission; exclud-
ing Chang 2011)
89.9 49.6 178 53.8 84.4
Serum lipase
(threshold: > twice
normal) (on admis-
89.9 91.9 178 30.6 25
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(Continued)
sion)
Serum
lipase (threshold: >
normal) (on admis-
sion)
89.9 91.9 20.6 30.6 26.9
Urinary trypsino-
gen-2 (threshold:
Actim Pancreatitis -
all studies; > 50 ng/
mL) (on admission)
89.9 91.9 57.4 59.2 59.4
Urinary
trypsinogen-
2 (threshold: Actim
Pancreatitis - sensi-
tivity analysis; > 50
ng/mL excluding
Aysan 2008) (on ad-
mission)
89.9 91.9 45.5 45.9 46
For each test with at least 2 studies, simpler models were fitted because of sparse data (Takwoingi 2015). The -2 log likelihood for
the different models for each meta-analysis is shown. The lowest -2 log likelihood ratio for each test is shown in bold italic font. The
corresponding model was used for meta-analysis
For each test with
studies, simpler models
ted because of
Takwoingi 2015
likelihood for
models for each meta-analysis
shown. The lowest
hood ratio for each
in bold italic font.
sponding model
meta-analysis
Appendix 11. Statistical methods that were planned but not performed because of paucity of data
The statistical analysis and data synthesis below were planned but could not be performed because of the paucity of data.
We planned to stratify the analysis by the different reference standards (i.e. we planned to use different reference standards as different
index tests). However, because of paucity of data, we did not stratify the studies based on reference standards.
We planned to compare the diagnostic accuracy of the different tests by including a single covariate term for test type in the bivariate
model to estimate differences in the sensitivity and specificity of the tests. We planned to consider a combination of tests for each of
the scenarios (any test positive or all tests positive) as different index tests. We planned to allow the variances of the random effects
and their covariance to also depend on test type, thus allowing the variances to differ between tests. We planned to use the hierarchical
summary receiver operating characteristics curve (HSROC) to test hypotheses about whether one test is superior to another and to
investigate heterogeneity (Rutter 2001). For this purpose, we planned to combine tests irrespective of the thresholds and reference
standards. We used the HSROC model to compare whether one test is superior to another since the HSROC model allows combining
tests regardless of the thresholds and might overcome the problem of a limited number of studies included under each threshold. In
case the study reported results at multiple thresholds, we used the threshold used by the authors for primary analysis for inclusion in
the HSROC model. We planned to use likelihood ratio tests to compare the model with and without covariate (test type). We planned
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to use a P value of less than 0.05 for the likelihood ratio test to indicate differences in diagnostic accuracy between the tests. We also
planned to compare the estimates of sensitivity and specificity between models to check the robustness of our assumptions about the
variances of the random effects. If at least four studies that evaluated different tests in the same study population were available (e.g. in
studies that perform more than one index test in all of the participants, individual index tests and combination of index tests in all of
the participants, or randomised controlled trials in which participants have been randomised to the different index tests), we planned
to perform a direct head-to-head comparison by limiting the test comparison to such studies. We also planned to present the relative
sensitivities and relative specificities of the index tests from the direct comparisons in a table.
We planned to create a graph of pre-test probabilities (using the observed median and range of prevalence from the included studies)
against post-test probabilities for each test stratified by different thresholds and reference standards. We planned to calculate the post-
test probabilities using these pre-test probabilities and the summary positive and negative likelihood ratios. We planned to report the
summary sensitivity, specificity, positive and negative likelihood ratios, and post-test probabilities for the median, lower quartile, and
upper quartile of the pre-test probabilities. However, because of paucity of data, we did not present the pre-test probability versus post-
test probability graph. We have not presented the likelihood ratios, as we had to provide the most important information in the table
for a number of comparisons.
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
1. Although we did not plan to include repeat tests in this review, the diagnostic test accuracy of these index tests on later days of
hospital might indicate the performance of these tests in patients with a prolonged period of symptoms. We have therefore analysed
and reported this information separately from the tests conducted on admission.
2. We have accepted visual inspection of pancreas during laparotomy or autopsy as a reference standard. This is at least as good as
radiological examination for the diagnosis of acute pancreatitis.
3. The other methods that we planned but could not perform because of paucity of data are listed in Appendix 11.
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